PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 26424290-10 2015 In contrast, QGYD and combination QGYD and ceftazidime treatment restored the elevated serum IL-1beta and Th1/Th2 levels to normal (P>0.05). Ceftazidime 43-54 interleukin 1 beta Rattus norvegicus 93-101 26666933-0 2015 Role of the Outer Membrane and Porins in Susceptibility of beta-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam. Ceftazidime 106-117 beta-lactamase Escherichia coli 59-73 26195508-0 2015 First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. Ceftazidime 16-27 KPC-3 Klebsiella pneumoniae 54-59 26709835-7 2015 However, only ceftazidime showed significant, dose dependent improvement in key metabolic variables including glucose, insulin, protein tyrosine tyrosine (PYY) and glucagon-like peptide-1 (GLP-1). Ceftazidime 14-25 glucagon Mus musculus 189-194 25915520-6 2015 VIM-24 (R228L) confers enhanced resistance to cephems and increases the rate of turnover compared to that of VIM-2 (kcat/KM increased by 6- and 10-fold for ceftazidime and cefepime, respectively). Ceftazidime 156-167 VIM-2 Pseudomonas aeruginosa 0-5 26100712-0 2015 In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Ceftazidime 22-33 KPC-3 Klebsiella pneumoniae 82-87 26071519-1 2015 OBJECTIVES: Spurred by the latest EUCAST and CLSI recommendation to adjust antibiotic therapy on the basis of MICs instead of resistance mechanisms, we aimed to investigate the ability of CTX-M-1 and CTX-M-14 to achieve ceftazidime resistance under selective conditions. Ceftazidime 220-231 CTX-M-1 Escherichia coli 188-208 26071519-4 2015 RESULTS: The CTX-M-1- and CTX-M-14-bearing clones switched from ceftazidime-susceptible to ceftazidime-resistant phenotypes under selective conditions within 24 h. However, no mutations within the bla CTX-M genes were found, and the efflux was unlikely to be involved in the increased ceftazidime MICs. Ceftazidime 64-75 CTX-M-14 Escherichia coli 26-34 26071519-4 2015 RESULTS: The CTX-M-1- and CTX-M-14-bearing clones switched from ceftazidime-susceptible to ceftazidime-resistant phenotypes under selective conditions within 24 h. However, no mutations within the bla CTX-M genes were found, and the efflux was unlikely to be involved in the increased ceftazidime MICs. Ceftazidime 91-102 CTX-M-14 Escherichia coli 26-34 26071519-4 2015 RESULTS: The CTX-M-1- and CTX-M-14-bearing clones switched from ceftazidime-susceptible to ceftazidime-resistant phenotypes under selective conditions within 24 h. However, no mutations within the bla CTX-M genes were found, and the efflux was unlikely to be involved in the increased ceftazidime MICs. Ceftazidime 91-102 CTX-M-14 Escherichia coli 26-34 25957381-3 2015 Two KPC-2 beta-lactamase variants that possessed elevated MICs of ceftazidime/avibactam were selected for further biochemical analyses. Ceftazidime 66-77 KPC-2 beta-lactamase Escherichia coli 4-24 25957381-5 2015 In contrast, several of the Arg164 and Asp179 variants of KPC-2 demonstrated MICs of ceftazidime/avibactam >8 mg/L. Ceftazidime 85-96 KPC-2 Escherichia coli 58-63 25957381-6 2015 beta-Lactamase kinetics showed that the Asp179Asn variant of KPC-2 demonstrated enhanced kinetic properties against ceftazidime. Ceftazidime 116-127 KPC-2 Escherichia coli 61-66 25957381-8 2015 CONCLUSIONS: Several KPC-2 variants demonstrating ceftazidime resistance as a result of single amino acid substitutions in the Omega-loop were not susceptible to ceftazidime/avibactam (MICs >8 mg/L). Ceftazidime 50-61 KPC-2 Escherichia coli 21-26 25957381-10 2015 As ceftazidime/avibactam is introduced into the clinic, monitoring for new KPC-2 variants that may exhibit increased ceftazidime kinetics as well as resistance to this novel antibiotic combination will be important. Ceftazidime 3-14 KPC-2 Escherichia coli 75-80 25957381-10 2015 As ceftazidime/avibactam is introduced into the clinic, monitoring for new KPC-2 variants that may exhibit increased ceftazidime kinetics as well as resistance to this novel antibiotic combination will be important. Ceftazidime 117-128 KPC-2 Escherichia coli 75-80 25662788-6 2015 One of three tazobactam/piperacillin-resistant strains with less susceptibility to ceftazidime overexpressed both blaCTX-M-15 and blaTEM-1, and the other two strains showed higher mRNA expression of either blaTEM-1 or blaOXA-1. Ceftazidime 83-94 beta-lactamase Escherichia coli 114-125 25662788-6 2015 One of three tazobactam/piperacillin-resistant strains with less susceptibility to ceftazidime overexpressed both blaCTX-M-15 and blaTEM-1, and the other two strains showed higher mRNA expression of either blaTEM-1 or blaOXA-1. Ceftazidime 83-94 class D beta-lactamase OXA-1 Escherichia coli 218-226 25793625-10 2015 The most important observation was the restoration of susceptibility of P. aeruginosa WUM226 to cefepime (MIC decrease from 32 to 4 mg/L) and ceftazidime (MIC decrease from 128 to 4 mg/L) in the presence of PAbetaN, which occurred despite an almost complete lack of beta-lactamase leakage from bacterial cells. Ceftazidime 142-153 Beta lactamase Pseudomonas aeruginosa 266-280 25713062-5 2015 Ceftazidime contains a large, bulky side chain that does not fit optimally in the wild-type TEM-1 active site. Ceftazidime 0-11 CD248 molecule Homo sapiens 92-97 26169413-10 2015 Median ceftazidime-avibactam MICs were higher against KPC-3 than KPC-2 variants (P = 0.02). Ceftazidime 7-18 KPC-3 Klebsiella pneumoniae 54-59 26169413-10 2015 Median ceftazidime-avibactam MICs were higher against KPC-3 than KPC-2 variants (P = 0.02). Ceftazidime 7-18 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 65-70 25167203-10 2014 CONCLUSION: Ceftazidime, but not gentamicin or meropenem reduced ureteric branching in mice and suggest a role for Fgf8 and Gdnf in its mechanism. Ceftazidime 12-23 fibroblast growth factor 8 Mus musculus 115-119 25167203-10 2014 CONCLUSION: Ceftazidime, but not gentamicin or meropenem reduced ureteric branching in mice and suggest a role for Fgf8 and Gdnf in its mechanism. Ceftazidime 12-23 glial cell line derived neurotrophic factor Mus musculus 124-128 25263503-9 2014 In the mouse study, although the rab-a-HMGB1 by itself could not improve the survival outcome of B. pseudomallei-infected mice, it could nevertheless enhance the effectiveness of suboptimal doses of ceftazidime in the treatment of these animals. Ceftazidime 199-210 high mobility group box 1 Mus musculus 39-44 24690213-9 2014 In the high-inoculum tests including isolates encoding CTX-M-14, ceftazidime was dramatically affected, with susceptibility decreasing from 82.1% of isolates inhibited at 4 mug/mL in the standard-inoculum tests to 0% at high inoculum. Ceftazidime 65-76 CTX-M-14 Escherichia coli 55-63 24792837-13 2014 Production of IMP-6 and VIM-2 MBLs is the main mechanisms in acquiring resistance to ceftazidime and carbapenems in P. aeruginosa isolates in Korea. Ceftazidime 85-96 VIM-2 Pseudomonas aeruginosa 24-29 23330672-3 2013 Here, we demonstrate that the amplified IS26-bla(SHV-5) units were arranged in tandems, containing up to more than 10 units, which could raise ceftazidime MICs for host strains from 4 mug mL(-1) to more than 128 mug mL(-1). Ceftazidime 143-154 beta-lactamase Escherichia coli 45-48 24342639-3 2014 Avibactam potentiated the activity of ceftazidime against organisms with combinations of ESBLs, AmpCs, and KPC-2. Ceftazidime 38-49 KPC-2 Pseudomonas aeruginosa 107-112 24379195-4 2014 The wild-type strain was susceptible to all of the agents, while the isogenic NDM-1-producing strain was resistant to ceftazidime, doripenem, and ertapenem. Ceftazidime 118-129 NDM-1 Klebsiella pneumoniae 78-83 24385326-8 2014 RESULTS: Ceftazidime and cephazolin in both types of PD solution retained more than 90% of their initial concentration for 168 and 336 hours respectively when stored at 4 C. Both of the antibiotics lost more than 10% of the initial concentration after 24 hours of storage at 25 or 37 C. Ceftazidime 9-20 olfactory receptor family 13 subfamily C member 7 (gene/pseudogene) Homo sapiens 278-285 24379200-0 2014 Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model. Ceftazidime 37-48 OXA-48 Klebsiella pneumoniae 95-101 24379200-2 2014 Efficacy has been demonstrated in vivo with ceftazidime against a ceftazidime-susceptible OXA-48 isolate but not with imipenem despite maintaining susceptibility. Ceftazidime 44-55 OXA-48 Klebsiella pneumoniae 90-96 24379200-2 2014 Efficacy has been demonstrated in vivo with ceftazidime against a ceftazidime-susceptible OXA-48 isolate but not with imipenem despite maintaining susceptibility. Ceftazidime 66-77 OXA-48 Klebsiella pneumoniae 90-96 24379200-7 2014 Consistent with low MICs, ceftazidime and levofloxacin exhibited efficacy against the isogenic OXA-48 strain, whereas doripenem did not, despite having a susceptible MIC; no activity was observed with ertapenem, consistent with a resistant MIC. Ceftazidime 26-37 OXA-48 Klebsiella pneumoniae 95-101 24379200-9 2014 Ceftazidime, levofloxacin, and ertapenem efficacy against isogenic and clinical OXA-48-producing strains correlated well with phenotypic profiles and pharmacodynamic targets, whereas efficacy with doripenem was variable over the MIC range studied. Ceftazidime 0-11 OXA-48 Klebsiella pneumoniae 80-86 24696553-12 2014 All ESBL producers demonstrated minimum inhibitory concentration levels >=2 mug/ml towards cefotaxime, ceftazidime and ceftriaxone. Ceftazidime 106-117 EsbL Escherichia coli 4-8 25500673-8 2014 More of the ESBL-positive isolates showed higher resistance to cefotaxime than to ceftazidime. Ceftazidime 82-93 EsbL Escherichia coli 12-16 24274894-9 2013 On initial screening with ceftriaxone (30 mug) disc showing resistance was then confirmed for ESBL production by phenotypic confirmatory disc diffusion test (PCDDT) using ceftazidime (30 ug) and ceftazidime + clavulanic acid (30 mug + 10ug) disc as per guidelines of CLSI (2011). Ceftazidime 171-182 EsbL Escherichia coli 94-98 24274894-9 2013 On initial screening with ceftriaxone (30 mug) disc showing resistance was then confirmed for ESBL production by phenotypic confirmatory disc diffusion test (PCDDT) using ceftazidime (30 ug) and ceftazidime + clavulanic acid (30 mug + 10ug) disc as per guidelines of CLSI (2011). Ceftazidime 195-206 EsbL Escherichia coli 94-98 24502096-10 2013 All ESBL isolates were susceptible to imipenem and resistant to ampicillin, piperacillin, cefazolin, cefotaxime, ceftazidime and cefepime. Ceftazidime 113-124 EsbL Escherichia coli 4-8 23671215-10 2013 CONCLUSIONS: A substantial portion of ESBL-producing isolates were susceptible to cefepime and ceftazidime by using the CLSI and EUCAST breakpoints. Ceftazidime 95-106 EsbL Escherichia coli 38-42 23529866-18 2013 Ceftriaxone, cefotaxime, ceftazidime, cefixime and cefepime have been studied in children and are all able to adequately penetrate the CSF. Ceftazidime 25-36 colony stimulating factor 2 Homo sapiens 135-138 23332427-15 2013 (n=41), MRSA (n=49) and cefotaxime- or ceftazidime-resistant Enterbacteriaceae (n=25), were isolated from 13% of patients with CAP and 23% of patients with HCAP. Ceftazidime 39-50 structural maintenance of chromosomes 3 Homo sapiens 156-160 23089750-7 2013 Time-dependent killing of ceftazidime was observed in PAO1 biofilms, but concentration-dependent killing activity of ceftazidime was observed for beta-lactamase-overproducing biofilms of P. aeruginosa in all three models. Ceftazidime 117-128 beta-lactamase Pseudomonas aeruginosa PAO1 146-160 23089750-13 2013 The inoculum effect of ceftazidime for the beta-lactamase-overproducing mutant PADeltaDDh2Dh3 biofilms was more obvious than for PAO1 biofilms, with a requirement of higher antibiotic concentration and a longer period of treatment. Ceftazidime 23-34 beta-lactamase Pseudomonas aeruginosa PAO1 43-57 24353573-3 2013 METHODOLOGY: Among 173 E. coli isolates, 82 were phenotypically detected as ESBL producers by standard cefotaxime / clavulanic acid and ceftazidime / clavulanic acid disc diffusion tests. Ceftazidime 136-147 EsbL Escherichia coli 76-80 23371303-17 2013 Potential future roles for ceftazidime-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ss-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ss-lactamases. Ceftazidime 27-38 beta-lactamase Klebsiella pneumoniae 251-255 23089750-3 2013 The purpose of this study was to investigate the role of beta-lactamase in the pharmacokinetics (PK) and pharmacodynamics (PD) of ceftazidime and imipenem on P. aeruginosa biofilms. Ceftazidime 130-141 Beta lactamase Pseudomonas aeruginosa 57-71 22938665-1 2012 OBJECTIVE: To observe the effects of rosiglitazone (RSG) and ceftazidime (CAZ) on peroxisome proliferator activated receptor gamma (PPARgamma) activity in nucleated cells and interleukin (IL-4, IL-6) levels in plasma in septic rats. Ceftazidime 61-72 peroxisome proliferator-activated receptor gamma Rattus norvegicus 82-130 23413710-4 2012 Nearly all isolates non-susceptible to ceftriaxone, ceftazidime and cefepime produced ESBL; the presence of CTX-M genes in the isolates correlated with a ceftriaxone non-susceptible phenotype. Ceftazidime 52-63 EsbL Escherichia coli 86-90 22938665-1 2012 OBJECTIVE: To observe the effects of rosiglitazone (RSG) and ceftazidime (CAZ) on peroxisome proliferator activated receptor gamma (PPARgamma) activity in nucleated cells and interleukin (IL-4, IL-6) levels in plasma in septic rats. Ceftazidime 61-72 peroxisome proliferator-activated receptor gamma Rattus norvegicus 132-141 22938665-1 2012 OBJECTIVE: To observe the effects of rosiglitazone (RSG) and ceftazidime (CAZ) on peroxisome proliferator activated receptor gamma (PPARgamma) activity in nucleated cells and interleukin (IL-4, IL-6) levels in plasma in septic rats. Ceftazidime 74-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 82-130 22938665-1 2012 OBJECTIVE: To observe the effects of rosiglitazone (RSG) and ceftazidime (CAZ) on peroxisome proliferator activated receptor gamma (PPARgamma) activity in nucleated cells and interleukin (IL-4, IL-6) levels in plasma in septic rats. Ceftazidime 74-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 132-141 22938665-8 2012 PPARgamma activity was significantly higher in CAZ group, RSG group and CAZ + RSG group than in sepsis group (0.282+-0.008, 0.336+-0.020, 0.347+-0.007 vs. 0.263+-0.017, all P<0.05), CAZ + RSG group>RSG group >CAZ group (both P<0.05). Ceftazidime 47-50 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-9 22938665-8 2012 PPARgamma activity was significantly higher in CAZ group, RSG group and CAZ + RSG group than in sepsis group (0.282+-0.008, 0.336+-0.020, 0.347+-0.007 vs. 0.263+-0.017, all P<0.05), CAZ + RSG group>RSG group >CAZ group (both P<0.05). Ceftazidime 72-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-9 22938665-8 2012 PPARgamma activity was significantly higher in CAZ group, RSG group and CAZ + RSG group than in sepsis group (0.282+-0.008, 0.336+-0.020, 0.347+-0.007 vs. 0.263+-0.017, all P<0.05), CAZ + RSG group>RSG group >CAZ group (both P<0.05). Ceftazidime 72-75 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-9 22826985-4 2012 ESBL phenotypic confirmatory test with ceftazidime, CTX and cefotaxime was performed for all urine isolates by disc diffusion method on Mueller-Hinton agar plates. Ceftazidime 39-50 EsbL Escherichia coli 0-4 22843686-0 2012 Exploring the role of a conserved class A residue in the Omega-Loop of KPC-2 beta-lactamase: a mechanism for ceftazidime hydrolysis. Ceftazidime 109-120 KPC-2 Escherichia coli 71-76 22843686-4 2012 When compared with wild type, 11 of 19 variants at position Arg-164 in KPC-2 conferred increased resistance to the oxyimino-cephalosporin, ceftazidime (minimum inhibitory concentration; 32 128 mg/liter) when expressed in Escherichia coli. Ceftazidime 139-150 KPC-2 Escherichia coli 71-76 22843686-5 2012 Using the R164S variant of KPC-2 as a representative beta-lactamase for more detailed analysis, we observed only a modest 25% increase in k(cat)/K(m) for ceftazidime (0.015 0.019 mum(-1) s(-1)). Ceftazidime 154-165 KPC-2 Escherichia coli 27-32 22843686-6 2012 Employing pre-steady-state kinetics and mass spectrometry, we determined that acylation is rate-limiting for ceftazidime hydrolysis by KPC-2, whereas deacylation is rate-limiting in the R164S variant, leading to accumulation of acyl-enzyme at steady-state. Ceftazidime 109-120 KPC-2 Escherichia coli 135-140 22843686-7 2012 CD spectroscopy revealed that a conformational change occurred in the turnover of ceftazidime by KPC-2, but not the R164S variant, providing evidence for a different form of the enzyme at steady state. Ceftazidime 82-93 KPC-2 Escherichia coli 97-102 22843686-9 2012 We propose that the R164S substitution in KPC-2 enhances ceftazidime resistance by proceeding through "covalent trapping" of the substrate by a deacylation impaired enzyme with a lower K(m). Ceftazidime 57-68 KPC-2 Escherichia coli 42-47 22330912-4 2012 Therefore, ceftazidime may be recommended for the treatment of infections due to OXA-48 producers if they do not coproduce an extended-spectrum beta-lactamase or a plasmid-mediated AmpC cephalosporinase. Ceftazidime 11-22 OXA-48 Klebsiella pneumoniae 81-87 20234775-2 2010 Because of a time delay in arranging a pars plana vitrectomy (PPV), the patient was treated with a prompt vitreous tap for culture an injection of vancomycin and ceftazidime. Ceftazidime 162-173 nuclear RNA export factor 1 Homo sapiens 115-118 22041508-8 2012 In conclusion, combinations of imipenem, cefepime and ceftazidime with avibactam may present a promising therapeutic strategy to treat infections due to K. pneumoniae with OXA-48 enzyme as well as K. pneumoniae and E. coli with CTX-M-15 enzyme. Ceftazidime 54-65 OXA-48 Klebsiella pneumoniae 172-178 21645522-5 2011 Comparison with VIM-2 and VIM-4 structures suggests an explanation for the reduced catalytic efficiency of VIM-7 against cephalosporins with a positively charged cyclic substituent at the C3 position (e.g., ceftazidime). Ceftazidime 207-218 vimentin Homo sapiens 16-19 21645522-5 2011 Comparison with VIM-2 and VIM-4 structures suggests an explanation for the reduced catalytic efficiency of VIM-7 against cephalosporins with a positively charged cyclic substituent at the C3 position (e.g., ceftazidime). Ceftazidime 207-218 vimentin Homo sapiens 26-29 21645522-8 2011 Docking of the cephalosporins ceftazidime and cefotaxime into the VIM-2 and VIM-7 structures reveals that amino acid substitutions may cause the mode of substrate binding to differ between the two enzymes. Ceftazidime 30-41 vimentin 2, pseudogene Homo sapiens 66-71 21645522-8 2011 Docking of the cephalosporins ceftazidime and cefotaxime into the VIM-2 and VIM-7 structures reveals that amino acid substitutions may cause the mode of substrate binding to differ between the two enzymes. Ceftazidime 30-41 vimentin Homo sapiens 66-69 20728316-6 2010 Twenty percent of ESBL-producing E. coli and 10% of ESBL-producing K. pneumoniae were susceptible to ceftazidime based on the CLSI 2010 guidelines. Ceftazidime 101-112 EsbL Escherichia coli 18-22 20728316-6 2010 Twenty percent of ESBL-producing E. coli and 10% of ESBL-producing K. pneumoniae were susceptible to ceftazidime based on the CLSI 2010 guidelines. Ceftazidime 101-112 EsbL Escherichia coli 52-56 20635454-6 2010 The cefotaxime and ceftazidime resistance of the ESBL-producers were transferred to azide-resistant E. coli J53 by conjugation. Ceftazidime 19-30 EsbL Escherichia coli 49-53 22719259-6 2012 This insertion creates the fused protein GCUF1-OXA-28 and modulates the transcription, the translation, and the secretion of the beta-lactamase in a Pseudomonas aeruginosa isolate (S-Pae) susceptible to the third generation cephalosporin ceftazidime. Ceftazidime 238-249 Beta lactamase Pseudomonas aeruginosa 129-143 22719259-8 2012 This resulted in the rearrangement of the integron gene cassette array, through excision of the gcuF1 cassette, and the full expression the beta-lactamase in an isolate (R-Pae) highly resistant to ceftazidime, which further spread to other patients within our hospital. Ceftazidime 197-208 Beta lactamase Pseudomonas aeruginosa 140-154 21382411-9 2011 Using M100-S20 criteria, 19% of ESBL-producing E. coli and 9% of ESBL-producing K. pneumoniae were susceptible to ceftazidime; 5% and 10% were susceptible to cefepime, respectively. Ceftazidime 114-125 EsbL Escherichia coli 32-36 21382411-9 2011 Using M100-S20 criteria, 19% of ESBL-producing E. coli and 9% of ESBL-producing K. pneumoniae were susceptible to ceftazidime; 5% and 10% were susceptible to cefepime, respectively. Ceftazidime 114-125 EsbL Escherichia coli 65-69 20070911-13 2010 Ceftazidime and cefotaxime resistance markers were present on the plasmidic DNA of both the bla(CTX-M-15) positive strains and were transmissible through conjugation. Ceftazidime 0-11 beta-lactamase Escherichia coli 92-95 19493866-7 2009 NXL104 restored the antimicrobial activity of ceftazidime, ceftriaxone, imipenem and piperacillin against Enterobacteriaceae strains producing KPC-2 or KPC-3. Ceftazidime 46-57 UBA domain containing 1 Homo sapiens 143-148 19664245-0 2009 In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa. Ceftazidime 96-107 Beta lactamase Pseudomonas aeruginosa 132-146 19664245-8 2009 CONCLUSION: Evaluation of in vitro antimicrobial effects on metallo-beta-lactamase-producing P. aeruginosa revealed relatively good effects of the 3-drug combination of aztreonam, ceftazidime and amikacin and marked effects of colistin. Ceftazidime 180-191 Beta lactamase Pseudomonas aeruginosa 68-82 19736945-1 2009 Extended-spectrum beta-lactamases (ESBLs) are derivatives of enzymes such as SHV-1 and TEM-1 that have undergone site-specific mutations that enable them to hydrolyze, and thus inactivate, oxyimino-cephalosporins, such as cefotaxime and ceftazidime. Ceftazidime 237-248 CD248 molecule Homo sapiens 87-92 19262076-2 2009 We evaluated the performance of MicroScan NegCombo Type 44 panel (Dade Behring, USA), which was developed to confirm ESBL-producing Enterobacteriaceae using ceftazidime/clavulanate and cefotaxime/clavulanate. Ceftazidime 157-168 EsbL Escherichia coli 117-121 19273683-4 2009 The CTX-M-53 beta-lactamase harbored the substitution Asp240Gly, like the CTX-M-15 enzyme, which is specifically implicated in a higher catalytic efficiency against ceftazidime. Ceftazidime 165-176 beta-lactamase Salmonella enterica 13-27 19372175-3 2009 A chance encounter with Ben de Pauw led to his introduction to clinical drug development research, introduced him to Peter Donnelly who was studying ceftazidime at the Hammersmith Hospital in London and led to a series of collaborative studies at the start of a distinguished research career. Ceftazidime 149-160 GTF2I repeat domain containing 1 Homo sapiens 24-27 19141747-5 2009 The prevalence and diversity of the CTX-M mutants, including CTX-M-15, CTX-M-27 and CTX-M-57, with significant hydrolytic activity against ceftazidime were increased. Ceftazidime 139-150 hypothetical protein Escherichia coli 61-69 18725449-1 2008 bla(CTX-M) genes, particularly bla(CTX-M-15), are the dominant extended-spectrum beta-lactamase (ESBL) genes among clinical isolates of Escherichia coli and Klebsiella pneumoniae in Sydney, Australia, where we also found one example of bla(CTX-M-62), encoding a novel enzyme conferring ceftazidime resistance. Ceftazidime 286-297 hypothetical protein Escherichia coli 35-43 18620848-2 2008 All strains harboured the bla(CTX-M-15) gene and presented minimum inhibitory concentrations for cefotaxime and ceftazidime of 256-1024 mg L(-1) and 16-512 mg L(-1), respectively, and eight of them showed different pulsed-field gel electrophoresis patterns. Ceftazidime 112-123 TEM beta-lactamase Klebsiella pneumoniae 26-29 18620848-2 2008 All strains harboured the bla(CTX-M-15) gene and presented minimum inhibitory concentrations for cefotaxime and ceftazidime of 256-1024 mg L(-1) and 16-512 mg L(-1), respectively, and eight of them showed different pulsed-field gel electrophoresis patterns. Ceftazidime 112-123 extended spectrum beta-lactamase CTX-M-15 Klebsiella pneumoniae 30-38 18559360-5 2008 Many of the resulting amino acid substitutions had significant effects on the in vivo activity of TEM-1, including up to a 64-fold increased activity toward ceftazidime and up to an 8-fold increased resistance to the inhibitor clavulanate. Ceftazidime 157-168 CD248 molecule Homo sapiens 98-103 18625770-1 2008 We passaged cells expressing TEM-1 and TEM-12 from a single plasmid through either ampicillin or ceftazidime. Ceftazidime 97-108 CD248 molecule Homo sapiens 29-34 18625770-2 2008 We found that the combined effects of recombination and selection removed the bla(TEM-1) allele from the bacterial population when it was passaged through ceftazidime or the bla(TEM-12) allele when cultures were passaged through ampicillin. Ceftazidime 155-166 CD248 molecule Homo sapiens 82-87 18559652-3 2008 A homology model suggests that the VIM-7 Tyr-218 Phe substitution may be responsible for the reduced catalytic efficiency against certain cephalosporins, including ceftazidime and cefepime. Ceftazidime 164-175 vimentin Homo sapiens 35-38 23055876-5 2008 RESULTS: THE FOLLOWING DRUGS WERE DEEMED COMPATIBLE WITH IBUPROFEN LYSINE: ceftazidime, epinephrine, furosemide, heparin lock flush, diluted insulin, morphine sulfate, phenobarbital, potassium chloride, and sodium bicarbonate. Ceftazidime 75-86 insulin Homo sapiens 141-148 17599307-3 2007 METHODS: In this randomized, placebo-controlled trial, we assessed the efficacy of lenograstim (granulocyte colony-stimulating factor [G-CSF], 263 mu g per day administered intravenously) in ceftazidime-treated patients with severe sepsis caused by suspected melioidosis in Thailand. Ceftazidime 191-202 colony stimulating factor 3 Homo sapiens 96-133 17999931-5 2008 In this work, we present the crystallographic structures of Asp240Gly-harboring enzyme CTX-M-16 in complex with ceftazidime-like glycylboronic acid (resolution 1.80 A) and molecular dynamics simulations of the corresponding acyl-enzyme complex. Ceftazidime 112-123 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 87-90 17999931-6 2008 These experiments revealed breathing motions of CTX-M enzymes and the role of the substitution Asp240Gly in the accommodation of ceftazidime. Ceftazidime 129-140 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 48-51 17999931-7 2008 The substitution Asp240Gly resulted in insertion of the C7 beta side chain of ceftazidime deep in the catalytic pocket and orchestrated motions of the active serine Ser70, the beta 3 strand and the omega loop, which favored the key interactions of the residues 237 and 235 with ceftazidime. Ceftazidime 78-89 endogenous retrovirus group K member 14 Homo sapiens 56-63 17999931-7 2008 The substitution Asp240Gly resulted in insertion of the C7 beta side chain of ceftazidime deep in the catalytic pocket and orchestrated motions of the active serine Ser70, the beta 3 strand and the omega loop, which favored the key interactions of the residues 237 and 235 with ceftazidime. Ceftazidime 278-289 endogenous retrovirus group K member 14 Homo sapiens 56-63 17949305-1 2007 In this report, we describe the detection of AmpC and CMY-2 beta-lactamases with the loss of OmpK35 porin among seven sporadic strains of ceftazidime-resistant Klebsiella pneumoniae and ceftazidime-resistant Escherichia coli. Ceftazidime 138-149 beta-lactamase Klebsiella pneumoniae 45-49 17949305-1 2007 In this report, we describe the detection of AmpC and CMY-2 beta-lactamases with the loss of OmpK35 porin among seven sporadic strains of ceftazidime-resistant Klebsiella pneumoniae and ceftazidime-resistant Escherichia coli. Ceftazidime 186-197 beta-lactamase Klebsiella pneumoniae 45-49 18173077-8 2007 It is important to use cefotaxime-cefotaxime/clavulanic acid as well as ceftazidime-ceftazidime/clavulanic acid ratio for detection of ESBL types that preferentially hydrolyze cefotaxime. Ceftazidime 72-83 EsbL Escherichia coli 135-139 18173077-8 2007 It is important to use cefotaxime-cefotaxime/clavulanic acid as well as ceftazidime-ceftazidime/clavulanic acid ratio for detection of ESBL types that preferentially hydrolyze cefotaxime. Ceftazidime 84-95 EsbL Escherichia coli 135-139 17576831-0 2007 Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. Ceftazidime 37-48 microphthalmia Japan Mus musculus 81-84 17662719-4 2007 Several deletion variants had enhanced activity towards ceftazidime compared to the wild-type TEM-1 demonstrating that removal of an amino acid can have a beneficial outcome. Ceftazidime 56-67 CD248 molecule Homo sapiens 94-99 19472726-4 2008 RESULTS: Beta-lactamase detection revealed that 9 of these strains had ceftazidime activity restored by cloxacillin and none of the 14 strains were metallo-beta-lactamase producing. Ceftazidime 71-82 Beta lactamase Pseudomonas aeruginosa 9-23 17253612-11 2007 Immunohistochemistry for NFkappaB showed strong positivity in saline and ceftazidime-treated mice in contrast to weak focal stain in ciprofloxacin- and dexamethasone-treated mice. Ceftazidime 73-84 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 25-33 18298053-1 2007 The bla(PER-1) presence was sought by PCR in 289 ceftazidime resistant Gram-negative bacteria isolated at Dokuz Eylul University Hospital (Turkey) between 1998 and 2003. Ceftazidime 49-60 Beta lactamase Pseudomonas aeruginosa 4-7 17434819-0 2007 In vitro selection and characterization of mutants in TEM-1-producing Escherichia coli by ceftazidime and ceftibuten. Ceftazidime 90-101 hypothetical protein Escherichia coli 54-59 17434819-1 2007 The present work was undertaken to study the ability of ceftazidime and ceftibuten to selectin vitro Escherichia coli HB101 harboring bla(TEM-1) beta-lactamase gene. Ceftazidime 56-67 hypothetical protein Escherichia coli 138-143 17434819-1 2007 The present work was undertaken to study the ability of ceftazidime and ceftibuten to selectin vitro Escherichia coli HB101 harboring bla(TEM-1) beta-lactamase gene. Ceftazidime 56-67 beta-lactamase Escherichia coli 145-159 17434819-4 2007 Ceftazidime created mutants that encode an extended-spectrum beta-lactamase (TEM-12) and exhibit decreased expression of OmpF. Ceftazidime 0-11 beta-lactamase Escherichia coli 61-75 17350305-9 2007 Ceftazidime, ceftazidime+tobramycin and meropenem reduced the CSF bacterial concentration at 8h by 2.5log10. Ceftazidime 0-11 colony stimulating factor 2 Homo sapiens 62-65 17350305-9 2007 Ceftazidime, ceftazidime+tobramycin and meropenem reduced the CSF bacterial concentration at 8h by 2.5log10. Ceftazidime 13-24 colony stimulating factor 2 Homo sapiens 62-65 17157873-12 2007 Previously, we have discovered that mutations G262S (yielding IMP-1) and G262A in IMP-6 stabilize the Zn(II) ligand His263 and thus the enzyme-substrate intermediate complex through a domino effect, which enhances conversion of drugs like ceftazidime, penicillins, and imipenem. Ceftazidime 239-250 insulin like growth factor 2 mRNA binding protein 1 Homo sapiens 62-67 18298053-3 2007 bla(PER-1) was detected in 46.2 and 35.9% of ceftazidime-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates, respectively. Ceftazidime 45-56 Beta lactamase Pseudomonas aeruginosa 0-3 16842579-0 2006 Development of high-level ceftazidime resistance via single-base substitutions of blaCTX-M-3 in hyper-mutable Escherichia coli. Ceftazidime 26-37 beta lactamase CTX-M-3 Escherichia coli 82-92 16816400-0 2006 High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp. Ceftazidime 61-72 histocompatibility minor 13 Homo sapiens 118-121 17051471-5 2006 Chromosomal hyperpoduction of K1 Beta-lactamase differs from all other ESBLs due its sensitivity to ceftazidime (Klebsiella oxytoca). Ceftazidime 100-111 beta-lactamase Klebsiella pneumoniae 33-47 17087095-3 2006 The authors examined the effect of four commonly used antimicrobial agents (ciprofloxacin, ceftazidime, cotrimoxazole and piperacillin-tazobactam) on tumour necrosis factor alpha (TNF alpha) production by human peripheral blood mononuclear cells (PBMC) stimulated with heat-killed S maltophilia. Ceftazidime 91-102 tumor necrosis factor Homo sapiens 180-189 17087095-6 2006 However at supratherapeutic concentrations, ceftazidime and ciprofloxacin, but not piperacillin-tazobactam, also inhibited significantly the production of TNF alpha. Ceftazidime 44-55 tumor necrosis factor Homo sapiens 155-164 16544267-3 2006 A critical examination of the literature provides divergent views of the effect of ESBL carriage on morbidity and mortality and suggests that ESBL production may have its most marked effect on ceftazidime. Ceftazidime 193-204 EsbL Escherichia coli 142-146 16613133-5 2006 From December 2003 to April 2005, a total of 58 potential ESBL-producing isolates (resistant to cefotaxime and/or ceftazidime) by BSAC disc susceptibility were tested by the combination discs and Vitek 2. Ceftazidime 114-125 EsbL Escherichia coli 58-62 16613133-11 2006 Further studies to compare Vitek 2 with cefotaxime and ceftazidime combination discs may reveal disc methodology for ESBL detection to be a more reliable alternative than using cefpodoxime combination discs alone. Ceftazidime 55-66 EsbL Escherichia coli 117-121 16898513-12 2006 We conclude that an empirical combination treatment of clarithromycine and ceftazidime is appropriate and effective in children with UTI caused by PA. Ceftazidime 75-86 alpha-1-microglobulin/bikunin precursor Homo sapiens 133-136 15722450-2 2005 The G262S point mutation distinguishing the metallo-beta-lactamase IMP-1 from IMP-6 has no effect on the hydrolysis of the drugs cephalothin and cefotaxime, but significantly improves catalytic efficiency toward cephaloridine, ceftazidime, benzylpenicillin, ampicillin, and imipenem. Ceftazidime 227-238 insulin like growth factor 2 mRNA binding protein 1 Homo sapiens 67-72 16544543-4 2005 Ceftazidime/ceftazidime-clavulanic acid and cefotaxime/cefotaxime-clavulanic acid rates were found as >8 and the results were accepted as positive for an ESBL. Ceftazidime 0-11 EsbL Escherichia coli 157-161 15781395-3 2005 Furthermore, most of the inhibitors enhanced the antibacterial activities of piperacillin (PIP) and ceftazidime (CAZ) particularly against TEM-1 and CTX-1 producing bacterial strains. Ceftazidime 100-111 hypothetical protein Escherichia coli 139-144 15781395-3 2005 Furthermore, most of the inhibitors enhanced the antibacterial activities of piperacillin (PIP) and ceftazidime (CAZ) particularly against TEM-1 and CTX-1 producing bacterial strains. Ceftazidime 113-116 hypothetical protein Escherichia coli 139-144 15750057-4 2005 All the isolates demonstrated resistance to ceftriaxone and ceftazidime due to the production of an extended-spectrum beta-lactamase (ESBL). Ceftazidime 60-71 beta-lactamase Salmonella enterica 118-132 15673739-7 2005 The K(m) value toward cefazolin (5.57 x 10(3) muM) was extremely high in comparison to those toward ceftazidime (30.9 muM) and penicillin G (67 muM), indicating its low affinity to cefazolin. Ceftazidime 100-111 latexin Homo sapiens 46-49 15673739-7 2005 The K(m) value toward cefazolin (5.57 x 10(3) muM) was extremely high in comparison to those toward ceftazidime (30.9 muM) and penicillin G (67 muM), indicating its low affinity to cefazolin. Ceftazidime 100-111 latexin Homo sapiens 118-121 15673739-7 2005 The K(m) value toward cefazolin (5.57 x 10(3) muM) was extremely high in comparison to those toward ceftazidime (30.9 muM) and penicillin G (67 muM), indicating its low affinity to cefazolin. Ceftazidime 100-111 latexin Homo sapiens 118-121 16115825-1 2005 OBJECTIVES: To investigate the resistance mechanisms of meropenem-resistant, ceftazidime-susceptible Pseudomonas aeruginosa isolates, in a clinical setting where VIM-2 or VIM-4 metallo-beta-lactamase (MBL)-producing pseudomonads are common. Ceftazidime 77-88 VIM-2 Pseudomonas aeruginosa 162-167 15949189-2 2005 Of the 250 E. coli isolates investigated, all of which came from patients in a major hospital in southern Lebanon, 61 (13.3%) were found to have ESBL, their production of beta-lactamase being confirmed by the ceftazidime and ceftazidime/clavulanic-acid disc methods. Ceftazidime 225-236 EsbL Escherichia coli 145-149 15728940-1 2005 We applied in vitro evolution to an Escherichia coli strain containing bla(CTX-M-2) and obtained 10 independent mutant bla(CTX-M-2) alleles that confer elevated resistance to ceftazidime (MIC > or = 32 microg/ml) but lost the ability to confer resistance to cefepime. Ceftazidime 175-186 beta-lactamase Escherichia coli 71-74 15728940-1 2005 We applied in vitro evolution to an Escherichia coli strain containing bla(CTX-M-2) and obtained 10 independent mutant bla(CTX-M-2) alleles that confer elevated resistance to ceftazidime (MIC > or = 32 microg/ml) but lost the ability to confer resistance to cefepime. Ceftazidime 175-186 beta-lactamase Escherichia coli 119-122 15928416-7 2005 RESULTS: OMP analysis revealed that cefoxitin and ceftazidime resistance was mediated by loss of a porin Omp K35 in the isolates of K.pneumoniae and E.coli. Ceftazidime 50-61 outer membrane protein Escherichia coli 9-12 15629222-4 2005 The ESBL-positive K. pneumoniae isolates were resistant to aztreonam, ceftazidime, aminoglycosides, and trimethoprim/sulfamethoxazole and susceptible to ciprofloxacin and tetracycline. Ceftazidime 70-81 CTX-M-15 Klebsiella pneumoniae 4-8 16110923-1 2005 In a fibrin-clot model of sepsis, developed in mice, treatment with the antibiotics ceftazidime (Cfz) and ofloxacin (Ofl) caused significant (p < 0.01) release of endotoxin and TNF-alpha after 4.5 h when compared with control (untreated) and amikacin (Ami) treated group. Ceftazidime 84-95 tumor necrosis factor Mus musculus 180-189 16110923-1 2005 In a fibrin-clot model of sepsis, developed in mice, treatment with the antibiotics ceftazidime (Cfz) and ofloxacin (Ofl) caused significant (p < 0.01) release of endotoxin and TNF-alpha after 4.5 h when compared with control (untreated) and amikacin (Ami) treated group. Ceftazidime 97-100 tumor necrosis factor Mus musculus 180-189 15928416-7 2005 RESULTS: OMP analysis revealed that cefoxitin and ceftazidime resistance was mediated by loss of a porin Omp K35 in the isolates of K.pneumoniae and E.coli. Ceftazidime 50-61 outer membrane protein Escherichia coli 105-108 15536141-0 2004 Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125. Ceftazidime 30-41 mucin 16, cell surface associated Homo sapiens 98-116 15752339-10 2005 CTX-M-15 or TEM-52 was especially responsible for the resistance to ceftazidime. Ceftazidime 68-79 hypothetical protein Escherichia coli 0-8 15752339-11 2005 CONCLUSIONS: These results appear to represent the in vivo evolution of CTX-M-type beta-lactamase genes (bla(CTX-M-3) --> bla(CTX-M-15)) under the selective pressure of antimicrobial therapy (especially ceftazidime). Ceftazidime 206-217 hypothetical protein Escherichia coli 129-137 15504890-0 2004 Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases. Ceftazidime 20-31 hypothetical protein Escherichia coli 116-121 15504890-1 2004 A strain of Escherichia coli containing TEM-1 and CTX-M-1 was tested in an in vitro pharmacokinetic model against ceftazidime with and without AM-112, a serine beta-lactamase inhibitor. Ceftazidime 114-125 hypothetical protein Escherichia coli 40-45 15504890-1 2004 A strain of Escherichia coli containing TEM-1 and CTX-M-1 was tested in an in vitro pharmacokinetic model against ceftazidime with and without AM-112, a serine beta-lactamase inhibitor. Ceftazidime 114-125 CTX-M-1 Escherichia coli 50-57 15536141-4 2004 OBJECTIVE: To determine whether IP cefazolin and ceftazidime increase peritoneal CA-125 appearance rate. Ceftazidime 49-60 mucin 16, cell surface associated Homo sapiens 81-87 15301679-1 2004 During a survey of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in Bulgaria in 2001-2002, three isolates from Sofia (two Escherichia coli, one Klebsiella pneumoniae) showed cefotaxime MICs that were decreased in the presence of clavulanate and were 2-8-fold higher than those of ceftazidime. Ceftazidime 303-314 EsbL Escherichia coli 19-51 17642726-3 2004 Fourteen percent and 12% of ESBL producers showed false susceptibility to ceftazidime and cefotaxime in routine susceptibility testing. Ceftazidime 74-85 EsbL Escherichia coli 28-32 15521206-6 2004 The ISPD guidelines for treatment of peritonitis recommended an empirical therapy based on the association of a first-generation cephalosporin with an aminoglycoside or ceftazidime. Ceftazidime 169-180 CDP-L-ribitol pyrophosphorylase A Homo sapiens 4-8 15155242-1 2004 A clinical strain of Escherichia coli isolated from pleural liquid with high levels of resistance to cefotaxime, ceftazidime, and aztreonam harbors a novel CTX-M gene (bla(CTX-M-32)) whose amino acid sequence differs from that of CTX-M-1 by a single Asp240-Gly substitution. Ceftazidime 113-124 beta-lactamase Escherichia coli 168-171 15155242-0 2004 High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution. Ceftazidime 25-36 CTX-M-1 Escherichia coli 89-96 15128727-9 2004 In neutropenic mice, survival was markedly better in the G-CSF + ceftazidime group compared with controls (P = 0.0001), G-CSF (P = 0.0002) or ceftazidime (P = 0.0172). Ceftazidime 65-76 colony stimulating factor 3 (granulocyte) Mus musculus 57-62 15128727-10 2004 In non-neutropenic mice, survival in the G-CSF + ceftazidime group (20%) was significantly higher than in the control and G-CSF groups (P = 0.0001) but not significantly higher than ceftazidime alone (9%) (P > 0.05). Ceftazidime 49-60 colony stimulating factor 3 (granulocyte) Mus musculus 41-46 15155242-1 2004 A clinical strain of Escherichia coli isolated from pleural liquid with high levels of resistance to cefotaxime, ceftazidime, and aztreonam harbors a novel CTX-M gene (bla(CTX-M-32)) whose amino acid sequence differs from that of CTX-M-1 by a single Asp240-Gly substitution. Ceftazidime 113-124 CTX-M-1 Escherichia coli 230-237 15281617-1 2004 A rapid and sensitive high-pressure liquid chromatographic method with simple sample preparation was developed for the quantitative analysis of the beta-lactam antibiotic ceftazidime (CAS 78439-06-2, Fortum). Ceftazidime 171-182 BCAR1 scaffold protein, Cas family member Homo sapiens 184-187 15164964-7 2004 Using ceftazidime as a marker for extended spectrum beta-lactamase (ESBL) expression, less than 3% of Escherichia coli or Klebsiella pneumoniae expressed this phenotype. Ceftazidime 6-17 EsbL Escherichia coli 68-72 14975053-9 2004 At 6 hours the IL-6 concentration was significantly lower in the ceftazidime group than in the saline group (P < 0.05), and in both the ceftazidime and the tobramycin groups there were significantly greater reductions from peak values (P < 0.05). Ceftazidime 65-76 interleukin 6 Homo sapiens 15-19 14975053-11 2004 However, our data indicate a possible anti-inflammatory effect exerted by both ceftazidime and tobramycin, which manifested as a significantly greater reduction in IL-6 in comparison with the untreated group. Ceftazidime 79-90 interleukin 6 Homo sapiens 164-168 15359102-7 2004 For the beta2M concentration, agreement remained good (rc >0.96) for ceftazidime and thimerosal (although the former tended to lower concentrations) but acetic acid was less optimal (rc = 0.893). Ceftazidime 72-83 beta-2-microglobulin Homo sapiens 8-14 14991988-1 2003 AIM: To investigate the inhibitory effect of egg white lysozyme (LZM) on ceftazidime (CFT)-induced release of endotoxin from Pseudomonas aeruginosa. Ceftazidime 73-84 lysozyme 2 Mus musculus 65-68 14582562-1 2003 With the overuse of expanded-spectrum cephalosporins, especially ceftazidime, outbreaks of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli infections have been reported. Ceftazidime 65-76 CTX-M-15 Klebsiella pneumoniae 91-123 12878527-6 2003 The ability of these compounds to protect ceftazidime from hydrolysis by beta-lactamase-producing strains was evaluated by MIC tests that combined ceftazidime and each oxapenem in a 1:1 or 2:1 ratio. Ceftazidime 42-53 Beta lactamase Pseudomonas aeruginosa 73-87 12878527-6 2003 The ability of these compounds to protect ceftazidime from hydrolysis by beta-lactamase-producing strains was evaluated by MIC tests that combined ceftazidime and each oxapenem in a 1:1 or 2:1 ratio. Ceftazidime 147-158 Beta lactamase Pseudomonas aeruginosa 73-87 14692154-16 2003 Finally, we tested our hypothesis in the rat model of chronic lung infection by assessing the effect of a beta ab raised by vaccination with purified chromosomal beta-lactamase on the outcome of the treatment with ceftazidime of bacteria resistant to beta-lactam antibiotics. Ceftazidime 214-225 amyloid beta precursor protein Rattus norvegicus 104-110 12775683-4 2003 Comparison of CTX-M-14 and CTX-M-27 showed that residue Gly-240 decreased Km for ceftazidime (205 versus 940 microM), but decreased hydrolytic activity against good substrates, such as cefotaxime (kcat, 113 versus 415 s-1), probably owing to the alteration of beta3 strand positioning during the catalytic process. Ceftazidime 81-92 CTX-M-14 Escherichia coli 14-22 12615876-4 2003 Detection of KPC-2 may be a problem for clinical laboratories because in this study it was associated with positive extended-spectrum beta-lactamase (ESBL) confirmation tests (clavulanate-potentiated activities of ceftriaxone, ceftazidime, cefepime and aztreonam). Ceftazidime 227-238 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 13-18 12507831-11 2003 Among Enterobacter spp., resistance (MIC>or=32 mg/l) to aztreonam, ceftazidime and ceftriaxone ranged from 12.3 to 21.2% over the 4 years, whereas resistance in Klebsiella (MIC>or=2 mg/l) ranged from 5.9 to 6.8%. Ceftazidime 70-81 histocompatibility minor 13 Homo sapiens 19-22 12843054-3 2003 For 21 of 131 (16%) isolates, the ESBL confirmatory test was positive; i.e., the BMD MICs of ceftazidime or cefotaxime decreased by >/=3 doubling dilutions in the presence of clavulanic acid (CA) or the disk diffusion zone diameters increased by >/=5 mm around ceftazidime or cefotaxime disks in the presence of CA. Ceftazidime 93-104 EsbL Escherichia coli 34-38 12843054-3 2003 For 21 of 131 (16%) isolates, the ESBL confirmatory test was positive; i.e., the BMD MICs of ceftazidime or cefotaxime decreased by >/=3 doubling dilutions in the presence of clavulanic acid (CA) or the disk diffusion zone diameters increased by >/=5 mm around ceftazidime or cefotaxime disks in the presence of CA. Ceftazidime 267-278 EsbL Escherichia coli 34-38 12730001-14 2003 Cefepime remained highly active, even against ceftazidime-resistant isolates of Enterobacter spp. Ceftazidime 46-57 histocompatibility minor 13 Homo sapiens 93-96 12517841-3 2003 ESBL production was confirmed by disk diffusion assay using cefpodoxime (CPD), cefotaxime (CTX), and ceftazidime (CTZ) with and without clavulanate (CLAV). Ceftazidime 101-112 EsbL Escherichia coli 0-4 12517841-3 2003 ESBL production was confirmed by disk diffusion assay using cefpodoxime (CPD), cefotaxime (CTX), and ceftazidime (CTZ) with and without clavulanate (CLAV). Ceftazidime 114-117 EsbL Escherichia coli 0-4 12935353-6 2003 Both ceftazidime and aztreonam enhanced LPS release from E. coli in comparison to low-level LPS release from imipenem-treated bacteria, consistent with observed differences in TNF-alpha release. Ceftazidime 5-16 tumor necrosis factor Mus musculus 176-185 14606607-3 2003 ESBL production was detected in 26 E. coli strains (5.96%), 60 K. pneumoniae strains (44.77%) and 15 K. oxytoca strains (26.78%) by ceftazidime/ceftazidime-clavulanate E-test. Ceftazidime 132-143 EsbL Escherichia coli 0-4 12645667-1 2002 To test the hypothesis that antibodies against the chromosomal beta-lactamase of Pseudomonas aeruginosa (a beta ab) might act as beta-lactamase inhibitors in patients with cystic fibrosis and chronic lung infection with P. aeruginosa, we compared in a rat model of chronic lung infection the efficacy of treatment with ceftazidime in beta-lactamase-immunized (group I) and non-immunized (group II) rats. Ceftazidime 319-330 amyloid beta precursor protein Rattus norvegicus 105-111 12645667-10 2002 Our study showed that a beta ab with beta-lactamase inhibitory activity raised by immunization with beta-lactamase can improve the outcome of treatment with ceftazidime of resistant P. aeruginosa in a rat model of chronic lung infection. Ceftazidime 157-168 amyloid beta precursor protein Rattus norvegicus 22-28 12427218-8 2002 CONCLUSIONS: It appears that a multiresistant transferable plasmid encoding the SHV-5 beta-lactamase, causing unusually high resistance to ceftazidime and aztreonam, and the combination AAC(6")-I + AAC(3)-I of acetylating enzymes causing, also resistance to all clinically available aminoglycosides, is established in K. pneumoniae in Greece. Ceftazidime 139-150 aminoglycoside acetyltransferase Klebsiella pneumoniae 186-195 12461028-0 2002 Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. Ceftazidime 28-39 beta lactamase CTX-M-3 Escherichia coli 126-148 12173800-10 2002 Pulmonary TNF-alpha, IL-beta, and IL-8 concentrations were attenuated in the ceftazidime group compared with those in the placebo group (p < 0.001, p = 0.02, and p = 0.003). Ceftazidime 77-88 tumor necrosis factor Homo sapiens 10-19 12121916-8 2002 Among the cytokines tested on days 0 to 15, we found an increased production of tumor necrosis factor alpha, KC (functional interleukin-8), and gamma interferon in the lungs of ceftazidime- and saline-treated controls compared to the moxifloxacin pretreatment that abolished their secretion. Ceftazidime 177-188 tumor necrosis factor Mus musculus 80-107 12121916-8 2002 Among the cytokines tested on days 0 to 15, we found an increased production of tumor necrosis factor alpha, KC (functional interleukin-8), and gamma interferon in the lungs of ceftazidime- and saline-treated controls compared to the moxifloxacin pretreatment that abolished their secretion. Ceftazidime 177-188 chemokine (C-X-C motif) ligand 15 Mus musculus 124-137 12173800-10 2002 Pulmonary TNF-alpha, IL-beta, and IL-8 concentrations were attenuated in the ceftazidime group compared with those in the placebo group (p < 0.001, p = 0.02, and p = 0.003). Ceftazidime 77-88 C-X-C motif chemokine ligand 8 Homo sapiens 34-38 11889308-16 2002 Although tumor necrosis factor-alpha plasma concentrations were significantly higher in the group treated with ceftazidime compared with the group treated with imipenem at the baseline and 4 hrs later, these differences were not statistically significant after 12 hrs of initiation of both treatments. Ceftazidime 111-122 tumor necrosis factor Homo sapiens 9-36 12108869-4 2002 Ceftazidime, tobramycin, and gentamycin slightly inhibited purified HNE activity whereas erythromycin and colistin significantly stimulated purified HNE and PE (395 and 557%, respectively). Ceftazidime 0-11 elastase, neutrophil expressed Homo sapiens 68-71 11740699-6 2002 A favorable response to treatment with a nonceftazidime ESC was observed when the causative pathogen produced either TEM-6 or TEM-12; ceftazidime treatment was associated with failure of therapy in all patients. Ceftazidime 44-55 tensin 3 Homo sapiens 117-122 11794426-4 2002 PATIENTS: Fifty-seven patients with cultures of presumed ESBL-producing (i.e., ceftazidime-resistant) E. coli or K. pneumoniae. Ceftazidime 79-90 EsbL Escherichia coli 57-61 11591698-8 2001 In addition, it was found that certain amino acid substitutions in the omega-loop region of the P99 enzyme result in increased ceftazidime hydrolysis suggesting the loop is an important determinant of substrate specificity. Ceftazidime 127-138 protein phosphatase 1 regulatory subunit 10 Homo sapiens 96-99 11953180-12 2002 The beta-lactamase from K. pneumoniae 99595 had stronger activity against ceftazidime, ceftaxime, and ceftriaxone than that from K. pneumoniae 99607. Ceftazidime 74-85 beta-lactamase Klebsiella pneumoniae 4-18 11502518-1 2001 A clinical isolate of Klebsiella pneumoniae was found to be resistant to ampicillin (MIC of 128 microg/ml), ticarcillin (MIC of 512 microg/ml), and ceftazidime (MIC of 128 microg/ml) and susceptible to all other beta-lactams; a synergistic effect between clavulanate and ceftazidime suggested the presence of an extended-spectrum beta-lactamase (ESBL). Ceftazidime 148-159 EsbL Escherichia coli 346-350 11320450-2 2001 The highest percentage of ESBL phenotype (defined as a minimum inhibitory concentration [MIC] > or =2 microg/mL for ceftazidime, ceftriaxone, or aztreonam) was detected among K. pneumoniae strains from Latin America (45%), followed by those from the Western Pacific region (25%), Europe (23%), the United States (8%), and Canada (5%). Ceftazidime 119-130 CTX-M-15 Klebsiella pneumoniae 26-30 11758235-5 2001 All ESBL(+) bacteria were sensitive to imipenam, the resistance rate of ESBL(+) bacteria to cefmetazole, amikacin and piperacillin/tazobactam was low; the in vitro activity of ceftazidim to ESBL(+) bacteria was high but the in vivo activity is still under study. Ceftazidime 176-186 EsbL Escherichia coli 4-8 11758235-5 2001 All ESBL(+) bacteria were sensitive to imipenam, the resistance rate of ESBL(+) bacteria to cefmetazole, amikacin and piperacillin/tazobactam was low; the in vitro activity of ceftazidim to ESBL(+) bacteria was high but the in vivo activity is still under study. Ceftazidime 176-186 EsbL Escherichia coli 72-76 11758235-5 2001 All ESBL(+) bacteria were sensitive to imipenam, the resistance rate of ESBL(+) bacteria to cefmetazole, amikacin and piperacillin/tazobactam was low; the in vitro activity of ceftazidim to ESBL(+) bacteria was high but the in vivo activity is still under study. Ceftazidime 176-186 EsbL Escherichia coli 72-76 11442343-2 2001 Of the 668 isolates, the 80 strains were presumptively defined as ESBL producers according to the result of disk method using ESBL marker antibiotics (aztreonam, ceftazidime, and cefoxitin). Ceftazidime 162-173 EsbL Escherichia coli 66-70 11478888-7 2001 The X-ray crystal structure of the mutant beta-lactamase GC1, which has improved activity against third-generation cephalosporins, suggests that a tandem tripeptide insertion in the Omega loop, which contains Val211, has caused a shift of this residue and also of Tyr221 that would allow ceftazidime and other third-generation cephalosporins to adopt a more catalytically competent conformation. Ceftazidime 288-299 solute carrier family 25 member 22 Homo sapiens 57-60 11810566-1 2000 Beta-lactamase production in Pseudomonas aeruginosa was determined in in-vitro models and in rat pouch infection models after exposure to ceftazidime, imipenem, and piperacillin. Ceftazidime 138-149 Beta lactamase Pseudomonas aeruginosa 0-14 11114163-2 2001 Natural variants of TEM-1 with increased antibiotic resistance have appeared in response to the use of extended-spectrum beta-lactam antibiotics (e.g., ceftazidime) and beta-lactamase inhibitors (e.g., clavulanic acid). Ceftazidime 152-163 CD248 molecule Homo sapiens 20-25 11810566-2 2000 Exposure of 28 P. aeruginosa strains to 1/4 minimum inhibitory concentration (MIC) of ceftazidime, imipenem, and piperacillin for 24 h enhanced intracellular beta-lactamase activities in 14, 22, and 6 strains, respectively, of the 28 clinical strains tested, and enhanced extracellular beta-lactamase activities which were not detected without exposure to antibiotics, in 7, 23, and 1 of the 28 strains, respectively. Ceftazidime 86-97 Beta lactamase Pseudomonas aeruginosa 158-172 11810566-2 2000 Exposure of 28 P. aeruginosa strains to 1/4 minimum inhibitory concentration (MIC) of ceftazidime, imipenem, and piperacillin for 24 h enhanced intracellular beta-lactamase activities in 14, 22, and 6 strains, respectively, of the 28 clinical strains tested, and enhanced extracellular beta-lactamase activities which were not detected without exposure to antibiotics, in 7, 23, and 1 of the 28 strains, respectively. Ceftazidime 86-97 Beta lactamase Pseudomonas aeruginosa 286-300 11110047-0 2000 Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase. Ceftazidime 56-67 Beta lactamase Pseudomonas aeruginosa 129-143 11810566-3 2000 Extracellular beta-lactamase activity from P. aeruginosa S-1278, producing an inducible beta-lactamase, scarcely increased after exposure to ceftazidime and piperacillin 24 h after incubation, while the activity increased after exposure to imipenem over the range of 1/8 to 8 MIC. Ceftazidime 141-152 Beta lactamase Pseudomonas aeruginosa 14-28 11810566-3 2000 Extracellular beta-lactamase activity from P. aeruginosa S-1278, producing an inducible beta-lactamase, scarcely increased after exposure to ceftazidime and piperacillin 24 h after incubation, while the activity increased after exposure to imipenem over the range of 1/8 to 8 MIC. Ceftazidime 141-152 Beta lactamase Pseudomonas aeruginosa 88-102 11036023-6 2000 However, BES-1 differed from CTX-M enzymes by its significant ceftazidime-hydrolyzing activity (k(cat), 25 s(-1)), high affinity for aztreonam (K(i), 1 microM), and lower susceptibility to tazobactam (50% inhibitory concentration [IC(50)], 0.820 microM) than to clavulanate (IC(50), 0.045 microM). Ceftazidime 62-73 BES-1 Serratia marcescens 9-14 11036058-1 2000 The effect of a single dose of ceftazidime on circulating concentrations of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in a rat model of sepsis was studied. Ceftazidime 31-42 interleukin 6 Rattus norvegicus 76-89 11036058-1 2000 The effect of a single dose of ceftazidime on circulating concentrations of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in a rat model of sepsis was studied. Ceftazidime 31-42 interleukin 6 Rattus norvegicus 91-95 11036058-1 2000 The effect of a single dose of ceftazidime on circulating concentrations of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in a rat model of sepsis was studied. Ceftazidime 31-42 tumor necrosis factor Rattus norvegicus 101-128 11036058-1 2000 The effect of a single dose of ceftazidime on circulating concentrations of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) in a rat model of sepsis was studied. Ceftazidime 31-42 tumor necrosis factor Rattus norvegicus 130-139 11036058-2 2000 IL-6 concentrations were significantly elevated (100 to 200 times the baseline) 6 h after ceftazidime administration in both septic and nonseptic (control) rats. Ceftazidime 90-101 interleukin 6 Rattus norvegicus 0-4 11110047-11 2000 It was shown that, during treatment with ceftazidime, biofilm-growing P. aeruginosa had the capacity to develop resistance due to the production of chromosomal beta-lactamase. Ceftazidime 41-52 Beta lactamase Pseudomonas aeruginosa 160-174 11050768-9 2000 Using the double-disc synergy test, extended-spectrum beta-lactamase (ESBL) was detected in 27.5% of ceftazidime-resistant clinical strains isolated in 1999. Ceftazidime 101-112 CTX-M-15 Klebsiella pneumoniae 36-68 10898697-3 2000 All variants obtained by submitting an Escherichia coli strain that contains a bla(TEM-1) gene to fluctuating challenge with both ceftazidime and amoxicillin contained only mutations previously detected in naturally occurring beta-lactamases. Ceftazidime 130-141 hypothetical protein Escherichia coli 83-88 10817740-0 2000 A new SHV-derived extended-spectrum beta-lactamase (SHV-24) that hydrolyzes ceftazidime through a single-amino-acid substitution (D179G) in the -loop. Ceftazidime 76-87 beta-lactamase Escherichia coli 36-50 10817740-1 2000 A new SHV-derived extended-spectrum beta-lactamase (SHV-24) conferring high-level resistance to ceftazidime but not cefotaxime and cefazolin was identified in Japan. Ceftazidime 96-107 beta-lactamase Escherichia coli 36-50 10722633-1 2000 Staphylococcus aureus killed during imipenem or ceftazidime chemotherapy in mice elicited an early release of tumor necrosis factor alpha (TNF-alpha) into the systemic circulation. Ceftazidime 48-59 tumor necrosis factor Mus musculus 110-137 10722633-1 2000 Staphylococcus aureus killed during imipenem or ceftazidime chemotherapy in mice elicited an early release of tumor necrosis factor alpha (TNF-alpha) into the systemic circulation. Ceftazidime 48-59 tumor necrosis factor Mus musculus 139-148 11025185-6 2000 For the extended-spectrum beta-lactamase (ESBL)-producing strain of Klebsiella pneumoniae, 18 (42%) of 43 laboratories testing ceftazidime correctly reported ceftazidime MICs in the resistant range. Ceftazidime 127-138 CTX-M-15 Klebsiella pneumoniae 8-40 11025185-6 2000 For the extended-spectrum beta-lactamase (ESBL)-producing strain of Klebsiella pneumoniae, 18 (42%) of 43 laboratories testing ceftazidime correctly reported ceftazidime MICs in the resistant range. Ceftazidime 158-169 CTX-M-15 Klebsiella pneumoniae 8-40 11050768-9 2000 Using the double-disc synergy test, extended-spectrum beta-lactamase (ESBL) was detected in 27.5% of ceftazidime-resistant clinical strains isolated in 1999. Ceftazidime 101-112 CTX-M-15 Klebsiella pneumoniae 70-74 10234838-2 1999 Clavulanic acid restored the ceftazidime activity, thus suggesting an extended spectrum beta-lactamase (ESBL). Ceftazidime 29-40 EsbL Escherichia coli 104-108 10706185-3 2000 Ciprofloxacin resistance was significantly linked to ceftazidime resistance, the hallmark of extended-spectrum beta-lactamase production, as well as to resistance to all antibiotic classes tested. Ceftazidime 53-64 beta-lactamase Klebsiella pneumoniae 111-125 10950626-6 2000 Several broad-spectrum beta-lactams ("fourth-generation" cephalosporins, carbapenems) are expected to be used with increasing frequency as a result of the emerging high rates of specific beta-lactamases that compromise the use of ceftriaxone, ceftazidime, and many beta-lactamase inhibition/ penicillin combinations. Ceftazidime 243-254 beta-lactamase Staphylococcus aureus 187-201 10103209-1 1999 DNA sequencing data showed that five clinical isolates of Escherichia coli with reduced susceptibility to ceftazidime, ceftriaxone, and cefotaxime contain an ampC gene that is preceded by a strong promoter. Ceftazidime 106-117 beta-lactamase Escherichia coli 158-162 9921053-0 1998 [Changes in ceftazidime concentration in the CSF following overdose in acute kidney failure]. Ceftazidime 12-23 colony stimulating factor 2 Homo sapiens 45-48 9876053-2 1998 ESBL production was demonstrated by an 8-fold reduction in the minimum inhibitory concentration (MIC) of ceftazidime combined with clavulanate (2 mg/L) compared to ceftazidime alone in all strains. Ceftazidime 105-116 CTX-M-15 Klebsiella pneumoniae 0-4 9876053-2 1998 ESBL production was demonstrated by an 8-fold reduction in the minimum inhibitory concentration (MIC) of ceftazidime combined with clavulanate (2 mg/L) compared to ceftazidime alone in all strains. Ceftazidime 164-175 CTX-M-15 Klebsiella pneumoniae 0-4 9756758-4 1998 It was found that the mechanism modulating ceftazidime hydrolysis in PSE-4 was different from that in TEM-1. Ceftazidime 43-54 CD248 molecule Homo sapiens 102-107 10049276-5 1999 In the control group (no CLDM), CAZ administration resulted in significant increases in endotoxin, TNF-alpha, and IL-1 beta concentrations. Ceftazidime 32-35 tumor necrosis factor Homo sapiens 99-108 10049276-5 1999 In the control group (no CLDM), CAZ administration resulted in significant increases in endotoxin, TNF-alpha, and IL-1 beta concentrations. Ceftazidime 32-35 interleukin 1 beta Homo sapiens 114-123 9784522-10 1998 Treatment of bacteria with the antibiotic ceftazidime significantly enhanced LP release. Ceftazidime 42-53 lipoprotein Escherichia coli 77-79 8818874-2 1996 The Etest (AB Biodisk, Solna, Sweden) ESBL screen uses stable gradient technology to evaluate the MIC of ceftazidime alone compared with the MIC of ceftazidime with clavulanic acid (2 micrograms/ml) to facilitate the recognition of strains expressing inhibitable enzymes. Ceftazidime 105-116 EsbL Escherichia coli 38-42 9687393-6 1998 Transformants producing only the pI 8.8 beta-lactamase were resistant to cefotaxime and aztreonam but were susceptible or intermediate to ceftazidime. Ceftazidime 138-149 Bla Salmonella enterica subsp. enterica serovar Typhimurium 40-54 9174192-9 1997 In addition, the MIC of ceftazidime for E. coli transconjugant GR202 (1 microg/ml) was lower than that for E. coli TEM-15 (16 microg/ml) and higher than that for E. coli IRT-4 or TEM-1 (0.06 microg/ml). Ceftazidime 24-35 hypothetical protein Escherichia coli 115-120 9186563-5 1997 The separate combinations of SYN-1012 and BRL-42715 with ceftazidime and cefotaxime provided comparable results against Gram-negatives, but not against Gram-positive isolates. Ceftazidime 57-68 joined toes Mus musculus 29-32 9593123-1 1998 A TEM-1 beta-lactamase derivative containing the single amino acid substitution A237T slightly increased (from 24 to 32 microg/ml) the cephalothin MIC for Escherichia coli RYC1000 but did not influence the activities of cefotaxime, ceftazidime, and aztreonam (MICs of 0.03, 0.12, and 0.06 microg/ml, respectively). Ceftazidime 232-243 TEM-1 beta-lactamase Escherichia coli 2-22 9371336-4 1997 The purified enzyme was studied from a kinetic point of view, revealing the highest catalytic efficiency (k[cat]/Km) values for ceftazidime and aztreonam compared with the TEM-1 prototype enzyme. Ceftazidime 128-139 TEM-1 Serratia marcescens 172-177 9184707-9 1997 Increased enzymuria, as indicated by increased urine concentrations of AAP and NAG, was observed in the gentamicin plus ceftazidime treatment (p < 0.05) compared with the other two treatments. Ceftazidime 120-131 O-GlcNAcase Homo sapiens 79-82 9184707-12 1997 Since acute elevations in AAP and NAG reflect insults to the kidney, these studies suggest that ceftazidime may enhance aminoglycoside-induced renal injury. Ceftazidime 96-107 O-GlcNAcase Homo sapiens 34-37 8818874-8 1996 The Etest ESBL screen test with the ceftazidime substrate appears to be a useful method for detecting or validating the presence of enteric bacilli potentially producing this type of beta-lactamase. Ceftazidime 36-47 EsbL Escherichia coli 10-14 8641311-3 1996 In contrast, alterations of OMP profiles were absent in most ceftazidime-resistant isolates. Ceftazidime 61-72 olfactory marker protein Homo sapiens 28-31 11862252-11 1996 At the end of therapy, 248 of 264 (94%) clinically evaluable patients receiving ceftazidime BID and 258 of 275% (94%) clinically evaluable patients receiving ceftazidime TID achieved clinical cure or improvement (p = 0.953). Ceftazidime 80-91 BH3 interacting domain death agonist Homo sapiens 92-95 18611753-4 1996 Expressed as a function of a standardized number of cells remaining after 6 h of exposure to gentamicin, ceftazidime, ciprofloxacin or imipenem, TNF leves associated with antibiotic exposure always exceeded those of controls. Ceftazidime 105-116 tumor necrosis factor Mus musculus 145-148 8815106-4 1996 Ceftazidime and aztreonam disks were equivalent in differentiating ESBL production, and both were superior to cefotaxime disks. Ceftazidime 0-11 EsbL Escherichia coli 67-71 8815106-7 1996 With a 5-micrograms ceftazidime disk, a breakpoint could be chosen with high sensitivity and specificity for ESBL-producing organisms. Ceftazidime 20-31 EsbL Escherichia coli 109-113 7768603-4 1995 After 4 h of incubation at 50 times the MIC, ceftazidime and ciprofloxacin treatment resulted in levels of endotoxin, TNF-alpha, and interleukin-6 significantly higher than those of imipenem and gentamicin (P < 0.001). Ceftazidime 45-56 tumor necrosis factor Homo sapiens 118-127 7540696-5 1995 METHODS: A randomized trial was conducted to test whether the administration of either G-CSF or GM-CSF improved the outcome of standard antibiotic therapy (ceftazidime plus amikacin) in nonleukemic cancer patients with fever (> 38 degrees C) and grade IV neutropenia (absolute neutrophil count [ANC] < 500/mm3) induced by standard-dose chemotherapy. Ceftazidime 156-167 colony stimulating factor 2 Homo sapiens 96-102 7545489-0 1995 Role of granulocyte colony-stimulating factor in preventing ceftazidime-induced myelosuppression in vitro. Ceftazidime 60-71 colony stimulating factor 3 Homo sapiens 8-45 7545489-3 1995 The present study was carried out to define the role of G-CSF in preventing the ceftazidime-induced suppression of BM progenitor cells in vitro, and to define the mechanisms involved in ceftazidime-induced myelosuppression. Ceftazidime 80-91 colony stimulating factor 3 Homo sapiens 56-61 7545489-4 1995 Our results show that G-CSF was able to maintain the proliferative activity of BM cells in the presence of ceftazidime if it was added to the culture medium during the early phase of exposure of BM to ceftazidime. Ceftazidime 107-118 colony stimulating factor 3 Homo sapiens 22-27 7752449-13 1995 MIC50 values show that TAZ/PIPC was two times less effective than CAZ and SBT/CPZ but four times more effective than CTM; furthermore, from the MIC90 values, TAZ/PIPC was four times more effective than PIPC, CTM and CAZ. Ceftazidime 216-219 tafazzin, phospholipid-lysophospholipid transacylase Homo sapiens 23-26 7545489-4 1995 Our results show that G-CSF was able to maintain the proliferative activity of BM cells in the presence of ceftazidime if it was added to the culture medium during the early phase of exposure of BM to ceftazidime. Ceftazidime 201-212 colony stimulating factor 3 Homo sapiens 22-27 7545489-5 1995 Monoclonal antibody to TNF completely inhibited the ceftazidime-induced myelosuppression. Ceftazidime 52-63 tumor necrosis factor Homo sapiens 23-26 7545489-8 1995 These data suggest that G-CSF prevents the ceftazidime-induced myelosuppression by antagonizing the suppressive effect of TNF and by enhancing the proliferative activity of BM. Ceftazidime 43-54 colony stimulating factor 3 Homo sapiens 24-29 7545489-8 1995 These data suggest that G-CSF prevents the ceftazidime-induced myelosuppression by antagonizing the suppressive effect of TNF and by enhancing the proliferative activity of BM. Ceftazidime 43-54 tumor necrosis factor Homo sapiens 122-125 7752449-13 1995 MIC50 values show that TAZ/PIPC was two times less effective than CAZ and SBT/CPZ but four times more effective than CTM; furthermore, from the MIC90 values, TAZ/PIPC was four times more effective than PIPC, CTM and CAZ. Ceftazidime 216-219 tafazzin, phospholipid-lysophospholipid transacylase Homo sapiens 158-161 8089110-0 1994 Characterization of TEM-1 beta-lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. Ceftazidime 115-126 CD248 molecule Homo sapiens 20-25 7695296-8 1995 Interestingly, the change from Gln to Lys at position 39 found in TEM-2, classically considered a neutral change, slightly but consistently increased the MIC of ceftazidime and aztreonam. Ceftazidime 161-172 RASD family member 2 Homo sapiens 66-71 18475677-1 1995 We investigated the effects of the antibiotic ceftazidime (CAZ) on the cytolytic action of the neutrophil myeloperoxidase-hydrogen peroxide-chloride anion system (MPO/H(2)O(2)/Cl(-)). Ceftazidime 46-57 myeloperoxidase Homo sapiens 106-121 18475677-1 1995 We investigated the effects of the antibiotic ceftazidime (CAZ) on the cytolytic action of the neutrophil myeloperoxidase-hydrogen peroxide-chloride anion system (MPO/H(2)O(2)/Cl(-)). Ceftazidime 46-57 myeloperoxidase Homo sapiens 163-166 18475677-1 1995 We investigated the effects of the antibiotic ceftazidime (CAZ) on the cytolytic action of the neutrophil myeloperoxidase-hydrogen peroxide-chloride anion system (MPO/H(2)O(2)/Cl(-)). Ceftazidime 59-62 myeloperoxidase Homo sapiens 106-121 18475677-1 1995 We investigated the effects of the antibiotic ceftazidime (CAZ) on the cytolytic action of the neutrophil myeloperoxidase-hydrogen peroxide-chloride anion system (MPO/H(2)O(2)/Cl(-)). Ceftazidime 59-62 myeloperoxidase Homo sapiens 163-166 7871780-0 1994 [A novel extended-spectrum beta-lactamase in a ceftazidime-resistant isolate of E. coli]. Ceftazidime 47-58 EsbL Escherichia coli 9-41 7871780-1 1994 A novel extended-spectrum beta-lactamase (ESbla) encoded on a plasmid of approximately 7.5kb, conferring resistance to beta-lactams tested except cefoxitin and imipenem, was found in a ceftazidime-resistant isolate of E. coli form our hospital. Ceftazidime 185-196 EsbL Escherichia coli 8-40 7871780-1 1994 A novel extended-spectrum beta-lactamase (ESbla) encoded on a plasmid of approximately 7.5kb, conferring resistance to beta-lactams tested except cefoxitin and imipenem, was found in a ceftazidime-resistant isolate of E. coli form our hospital. Ceftazidime 185-196 EsbL Escherichia coli 42-47 8067751-0 1994 Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime. Ceftazidime 182-193 TEM-1 beta-lactamase Escherichia coli 68-88 8067751-2 1994 The Arg-164-->Ser mutation in the TEM-1 beta-lactamase (TEM-12 enzyme) is known to enhance the activity of the enzyme against ceftazidime, resulting in resistance to the drug in a strain producing the mutant enzyme (D. A. Weber, C. C. Sanders, J. S. Bakken, and J. P. Quinn, J. Infect. Ceftazidime 129-140 TEM-1 beta-lactamase Escherichia coli 37-57 8067751-5 1994 The doubly mutated derivative of the TEM-1 enzyme (Ser-164/Ser-244) retains the characteristics of the Ser-164 mutant enzyme, i.e., enhanced activity against ceftazidime and sensitivity to inactivation by clavulanate. Ceftazidime 158-169 hypothetical protein Escherichia coli 37-42 8331207-4 1993 After intravenous administration, the pharmacokinetic parameters of ceftazidime were: elimination plasma half-life (t1/2 beta) = 24.6 +/- 4.6 hours; apparent volume of distribution (V(area)): 0.37 +/- 0.09 1/kg, total plasma clearance (CL): 11.9 +/- 3.3 mL/minute, peritoneal clearance (CLp): 1.7 +/- 0.3 mL/minute. Ceftazidime 68-79 interleukin 1 receptor like 1 Homo sapiens 116-125 8517725-1 1993 Klebsiella pneumoniae NU2936 was isolated from a patient and was found to produce a plasmid-encoded beta-lactamase (MOX-1) which conferred resistance to broad spectrum beta-lactams, including moxalactam, flomoxef, ceftizoxime, cefotaxime, and ceftazidime. Ceftazidime 243-254 beta-lactamase Klebsiella pneumoniae 100-114 8517725-1 1993 Klebsiella pneumoniae NU2936 was isolated from a patient and was found to produce a plasmid-encoded beta-lactamase (MOX-1) which conferred resistance to broad spectrum beta-lactams, including moxalactam, flomoxef, ceftizoxime, cefotaxime, and ceftazidime. Ceftazidime 243-254 mesenchyme homeobox 1 Homo sapiens 116-121 8129347-11 1993 Pseudomonas spp was isolated in 8.6% of cases and was generally sensitive to ceftazidime and amikacin. Ceftazidime 77-88 histocompatibility minor 13 Homo sapiens 12-15 8360130-9 1993 However, in patients with pneumonia ceftazidime was significantly more effective than imipenem/cilastatin in clearing patients of Pseudomonas spp. Ceftazidime 36-47 histocompatibility minor 13 Homo sapiens 142-145 8360130-13 1993 Monotherapy with either ceftazidime (2 g bid) or imipenem/cilastatin (0.5 g qid) is safe and effective and could be considered as an alternative to combination therapy for the treatment of serious hospital-acquired infections. Ceftazidime 24-35 BH3 interacting domain death agonist Homo sapiens 41-44 8331207-4 1993 After intravenous administration, the pharmacokinetic parameters of ceftazidime were: elimination plasma half-life (t1/2 beta) = 24.6 +/- 4.6 hours; apparent volume of distribution (V(area)): 0.37 +/- 0.09 1/kg, total plasma clearance (CL): 11.9 +/- 3.3 mL/minute, peritoneal clearance (CLp): 1.7 +/- 0.3 mL/minute. Ceftazidime 68-79 calmodulin like 3 Homo sapiens 236-238 8331207-4 1993 After intravenous administration, the pharmacokinetic parameters of ceftazidime were: elimination plasma half-life (t1/2 beta) = 24.6 +/- 4.6 hours; apparent volume of distribution (V(area)): 0.37 +/- 0.09 1/kg, total plasma clearance (CL): 11.9 +/- 3.3 mL/minute, peritoneal clearance (CLp): 1.7 +/- 0.3 mL/minute. Ceftazidime 68-79 calmodulin like 3 Homo sapiens 287-290 8486571-9 1993 However, for both cefuroxime and ceftazidime-treated cultures, low-dose treatment resulted in significantly higher production of TNF. Ceftazidime 33-44 tumor necrosis factor Homo sapiens 129-132 8486571-10 1993 The differences in TNF production between these antibiotics could be explained by the production of filaments following treatment with cefuroxime, aztreonam and low-dose ceftazidime, resulting in late bacterial lysis with high levels of endotoxin, whereas treatment with imipenem or high-dose ceftazidime resulted in the formation of spheroplasts, resulting in early lysis of the bacteria and much lower levels of endotoxin. Ceftazidime 170-181 tumor necrosis factor Homo sapiens 19-22 8486571-10 1993 The differences in TNF production between these antibiotics could be explained by the production of filaments following treatment with cefuroxime, aztreonam and low-dose ceftazidime, resulting in late bacterial lysis with high levels of endotoxin, whereas treatment with imipenem or high-dose ceftazidime resulted in the formation of spheroplasts, resulting in early lysis of the bacteria and much lower levels of endotoxin. Ceftazidime 293-304 tumor necrosis factor Homo sapiens 19-22 8380814-4 1993 Protection against myeloperoxidase and H2O2 was also observed with the thioether-containing antibiotics, ticarcillin and ceftazidime, but at higher concentrations than with the aminoglycosides. Ceftazidime 121-132 myeloperoxidase Homo sapiens 19-34 1583320-1 1992 The relative effects of two beta-lactam antibiotics, penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime, upon in vitro induction of lipopolysaccharide (LPS) release were investigated against smooth- and rough-LPS mutant isolates of Pseudomonas aeruginosa. Ceftazidime 125-136 dedicator of cyto-kinesis 3 Mus musculus 110-113 1590704-4 1992 We found that the beta-lactamase activity increased to high levels in sputum from patients with CF during the course of piperacillin, ceftazidime, cefsulodin, or imipenem therapy. Ceftazidime 134-145 Beta lactamase Pseudomonas aeruginosa 18-32 1583320-2 1992 Free LPS liberated from both isolates are 10- to 40-fold higher for ceftazidime-exposed cultures than control or imipenem-treated cultures after 4-8 h at 35 degrees C despite equivalent MICs. Ceftazidime 68-79 toll-like receptor 4 Mus musculus 5-8 1583320-4 1992 Sub-MIC levels of ceftazidime induced filamentation and LPS release without significant bacterial lysis. Ceftazidime 18-29 toll-like receptor 4 Mus musculus 56-59 1583320-6 1992 Sub-MIC levels of imipenem released relatively small amounts of free LPS while reducing colony counts approximately 2 logs more than equivalent amounts of ceftazidime after 2 h. Data suggest that ceftazidime-induced filamentation releases larger quantities of bioreactive LPS than nonfilamentous fast-lysing imipenem. Ceftazidime 196-207 toll-like receptor 4 Mus musculus 69-72 1583320-6 1992 Sub-MIC levels of imipenem released relatively small amounts of free LPS while reducing colony counts approximately 2 logs more than equivalent amounts of ceftazidime after 2 h. Data suggest that ceftazidime-induced filamentation releases larger quantities of bioreactive LPS than nonfilamentous fast-lysing imipenem. Ceftazidime 196-207 toll-like receptor 4 Mus musculus 272-275 2289997-6 1990 For ceftazidime and ceftriaxone similar changes of t1/2 and Vd are observed. Ceftazidime 4-15 interleukin 1 receptor like 1 Homo sapiens 51-62 1384868-5 1992 In the ELISA inhibition test, Az-1 and Az-2 were inhibited from binding to aztreonam-HSA by aztreonam, ceftazidime, aztreonam hydrolysate, aztreonam-epsilon-amino-n-caproic acid (EACA) and ceftazidime-EACA. Ceftazidime 103-114 centrosomal protein 131 Homo sapiens 30-34 1384868-5 1992 In the ELISA inhibition test, Az-1 and Az-2 were inhibited from binding to aztreonam-HSA by aztreonam, ceftazidime, aztreonam hydrolysate, aztreonam-epsilon-amino-n-caproic acid (EACA) and ceftazidime-EACA. Ceftazidime 103-114 ornithine decarboxylase antizyme 2 Homo sapiens 39-43 1384868-9 1992 Furthermore, the MAb showed no inhibitory reaction with various beta-lactams except aztreonam- and ceftazidime-EACA conjugates in the ELISA inhibition test, suggesting that Az-3 recognize a new antigenic determinant (NAD), which is formed by the conjugation of beta-lactam and carrier protein. Ceftazidime 99-110 ornithine decarboxylase antizyme 3 Homo sapiens 173-177 1894940-7 1991 Ceftazidime, aztreonam, and cefotaxime killed E. coli at a slower rate and were associated with significant increases in mononuclear cell TNF responses. Ceftazidime 0-11 tumor necrosis factor Homo sapiens 138-141 1384868-3 1992 In ELISA, Az-1 and Az-2 reacted only with aztreonam and ceftazidime, which have the same acyl side chain. Ceftazidime 56-67 centrosomal protein 131 Homo sapiens 10-23 34827256-1 2021 Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Ceftazidime 0-11 OXA-48 Klebsiella pneumoniae 74-80 34935416-1 2021 Recently, various blaKPC-2 variants resistant to ceftazidime-avibactam have begun to emerge in clinical settings, but it is unclear which testing method is most appropriate for detecting these variants. Ceftazidime 49-60 KPC-2 protein Klebsiella pneumoniae 18-26 34935448-7 2021 Kinetic parameters showed that KPC-71, compared to wild-type KPC-2, exhibited a lower (~13-fold) Km with ceftazidime and a higher (~14-fold) 50% inhibitory concentration with avibactam. Ceftazidime 105-116 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 61-66 34984104-5 2022 The isolates were screened for ESBL production by the double-disk synergy test using Ceftazidime (30 mug) and Cefotaxime (30 mug) disks and confirmed by combined disk diffusion test using Clavulanic acid. Ceftazidime 85-96 EsbL Escherichia coli 31-35 34747363-10 2021 The mutations both on the KPC-3 enzyme and in the porins confirmed, that diverse mechanisms confer resistance to ceftazidime/avibactam in K. pneumoniae. Ceftazidime 113-124 KPC-3 Klebsiella pneumoniae 26-31 34854060-14 2022 All OXA-48 producers were susceptible to CAZ/AVI and plazomicin. Ceftazidime 41-44 OXA-48 Klebsiella pneumoniae 4-10 34827256-0 2021 In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of beta-Lactam Plus Novel beta-Lactamase Inhibitor or beta-Lactam Enhancer Combinations. Ceftazidime 22-33 OXA-48 Klebsiella pneumoniae 58-64 34827256-9 2021 The present work revealed the possibility of ceftazidime/avibactam resistance in OXA-48-like K. pneumoniae through mutations in proteins involved in efflux and/or porins without concomitant fitness cost mandating astute monitoring of ceftazidime/avibactam resistance among OXA-48 genotypes. Ceftazidime 45-56 OXA-48 Klebsiella pneumoniae 81-87 34827216-14 2021 Both ceftazidime and cefepime showed very good inhibitory activity towards SARS CoV-2"s Mpro, with IC50 values of 1.81 microM and 8.53 microM, respectively. Ceftazidime 5-16 NEWENTRY Severe acute respiratory syndrome-related coronavirus 88-92 34882368-15 2021 Finally, boronic acid test using 600 mug/mL PBA with 30microg ceftazidime, as phenotypic method for detecting AmpC beta- lactamases, was ranked very good for marking negative tests. Ceftazidime 62-73 beta-lactamase Escherichia coli 110-114 34538993-6 2021 Upon testing the binding score with SARS-CoV-2 Spike protein it was revealed that 4c exhibited the highest score (-7.22 kcal/mol) compared to the reference antibacterial drug Ceftazidime (-6.36 kcal/mol). Ceftazidime 175-186 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 47-52 34408414-9 2021 Results: The nanofibrous fixators released vancomycin, ceftazidime, and lidocaine in a sustained manner under both in vitro and in vivo conditions and protected BMP-2 from burst release. Ceftazidime 55-66 bone morphogenetic protein 2 Homo sapiens 161-166 34430873-10 2021 Conclusions: Hyperproduction of chromosomal AmpC appears to be the most common mechanism of resistance to ceftazidime and/or cefepime in E. cloacae and C. freundii. Ceftazidime 106-117 beta lactamase DHA-1 Citrobacter freundii 44-48 32427286-0 2021 Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales. Ceftazidime 12-23 mannose-binding lectin family member 3, pseudogene Homo sapiens 99-102 34184916-8 2021 With respect to antibiotic resistance, we discovered that a combination of mutations in pathoadaptive genes (phoQ and bigR) and two other genes encoding regulatory proteins (spoT and cpxA) were associated with increased resistance to meropenem and ceftazidime. Ceftazidime 248-259 cell adhesion molecule 3 Homo sapiens 118-122 34112764-0 2021 Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction. Ceftazidime 15-26 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 100-105 34112764-0 2021 Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction. Ceftazidime 15-26 angiotensin converting enzyme 2 Homo sapiens 114-118 34354959-0 2021 Acquisition of a Stable and Transferable bla NDM-5-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment. Ceftazidime 101-112 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 137-142 34354959-14 2021 Our study described the acquisition of a bla NDM-5-harboring plasmid leading to resistance to ceftazidime/avibactam in KPC-2-producing Klebsiella pneumoniae during treatment. Ceftazidime 94-105 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 119-124 34795702-10 2021 Fifty-four isolates of ESBL-producing E. coli showed a high level of resistance to amoxicillin clavulanic acid (83.3%), ciprofloxacin (83.3%), and ceftazidime (79.6%). Ceftazidime 147-158 EsbL Escherichia coli 23-27 35613352-9 2022 The isolates belonged to 17 different STs, including 5 new STs; ST4 was the most prevalent ST. Resistance to ceftazidime was observed in 60% of strains, to ticarcillin-clavulanate - in 32%, to levofloxacin - in 24%, to trimethoprim/sulfamethoxazole - in 12% of strains. Ceftazidime 109-120 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 Homo sapiens 64-67 34189161-2 2021 The sequencing of a target region showed that it harbored a KPC-3 variant enzyme (D179Y; KPC-31), which confers resistance to ceftazidime-avibactam and restores meropenem susceptibility. Ceftazidime 126-137 KPC-3 Klebsiella pneumoniae 60-65 35613352-11 2022 All ST4 isolates were resistant or intermediate to ceftazidime and ticarcillin-clavulanate. Ceftazidime 51-62 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 Homo sapiens 4-7 35461077-0 2022 Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Ceftazidime 13-24 KPC-2 protein Klebsiella pneumoniae 61-69 35588280-4 2022 In contrast with blaKPC-2, the emergent mutations within the Omega-loop conferred high-level resistance to ceftazidime-avibactam with a sharp reduction of carbapenemase activity. Ceftazidime 107-118 KPC-2 protein Klebsiella pneumoniae 17-25 35588280-7 2022 Such blaKPC-2 variants first appeared after 9 to 18 days of ceftazidime-avibactam usage, but the lack of its feasible detection method often led to the assumption of ceftazidime-avibactam sensitivity resulting in clinical incorrect usage. Ceftazidime 60-71 KPC-2 protein Klebsiella pneumoniae 5-13 35588280-7 2022 Such blaKPC-2 variants first appeared after 9 to 18 days of ceftazidime-avibactam usage, but the lack of its feasible detection method often led to the assumption of ceftazidime-avibactam sensitivity resulting in clinical incorrect usage. Ceftazidime 166-177 KPC-2 protein Klebsiella pneumoniae 5-13 35563520-0 2022 Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents. Ceftazidime 52-63 CD274 antigen Mus musculus 20-24 35190875-0 2022 Molecular recognition and binding of CcrA from Bacteroides fragilis with cefotaxime and ceftazidime by fluorescence spectra and molecular docking. Ceftazidime 88-99 cfiA Bacteroides fragilis 37-41 35311523-2 2022 Herein, the basis of susceptibility to carbapenems and resistance to ceftazidime (CAZ) and CZA of the D179Y variant of KPC-2 and -3 was explored. Ceftazidime 69-80 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 119-131 35311523-2 2022 Herein, the basis of susceptibility to carbapenems and resistance to ceftazidime (CAZ) and CZA of the D179Y variant of KPC-2 and -3 was explored. Ceftazidime 82-85 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 119-131 35341315-3 2022 To gain insights into ceftazidime-avibactam resistance conferred by D179N/Y variants of KPC-2, crystal structures of these variants were determined. Ceftazidime 22-33 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 88-93 35341315-8 2022 We postulate that the KPC-2 variants can accommodate ceftazidime because the Omega loop is displaced in D179Y or can be more readily displaced in D179N KPC-2. Ceftazidime 53-64 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 22-27 35341315-8 2022 We postulate that the KPC-2 variants can accommodate ceftazidime because the Omega loop is displaced in D179Y or can be more readily displaced in D179N KPC-2. Ceftazidime 53-64 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 152-157 35341315-10 2022 Overall, the structural results regarding KPC-2 D179 variants revealed various degrees of destabilization of the Omega loop that contribute to ceftazidime-avibactam resistance, possible substrate-assisted catalysis of ceftazidime, and meropenem and meropenem-vaborbactam susceptibility. Ceftazidime 143-154 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 42-47 35341315-10 2022 Overall, the structural results regarding KPC-2 D179 variants revealed various degrees of destabilization of the Omega loop that contribute to ceftazidime-avibactam resistance, possible substrate-assisted catalysis of ceftazidime, and meropenem and meropenem-vaborbactam susceptibility. Ceftazidime 218-229 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 42-47 35190875-1 2022 In search of new super-bacterial inhibitor agents, the recognition and binding mechanism of the B1 subclass MbetaL CcrA from Bacteroides fragilis with cefotaxime (CTX) and ceftazidime (CAZ) were studied using spectroscopy analysis and molecular docking. Ceftazidime 172-183 cfiA Bacteroides fragilis 115-119 35190875-1 2022 In search of new super-bacterial inhibitor agents, the recognition and binding mechanism of the B1 subclass MbetaL CcrA from Bacteroides fragilis with cefotaxime (CTX) and ceftazidime (CAZ) were studied using spectroscopy analysis and molecular docking. Ceftazidime 185-188 cfiA Bacteroides fragilis 115-119 35190875-2 2022 The results showed that the fluorescence quenching of CcrA induced by CTX and CAZ were all due to the complex formation, which belonged to static quenching and was forced by hydrogen bonds and Van der Waals forces, despite the greater binding ability of CTX with CcrA than CAZ. Ceftazidime 78-81 cfiA Bacteroides fragilis 54-58 35190875-2 2022 The results showed that the fluorescence quenching of CcrA induced by CTX and CAZ were all due to the complex formation, which belonged to static quenching and was forced by hydrogen bonds and Van der Waals forces, despite the greater binding ability of CTX with CcrA than CAZ. Ceftazidime 78-81 cfiA Bacteroides fragilis 263-267 35190875-2 2022 The results showed that the fluorescence quenching of CcrA induced by CTX and CAZ were all due to the complex formation, which belonged to static quenching and was forced by hydrogen bonds and Van der Waals forces, despite the greater binding ability of CTX with CcrA than CAZ. Ceftazidime 273-276 cfiA Bacteroides fragilis 54-58 35190875-4 2022 In addition, the whole antibiotic molecule ultimately entered the active pocket of CcrA with its original carbonate replaced by the carboxyl oxygen of the hexatomic ring adjacent to the beta-lactam ring in CTX or CAZ, forming a new tetrahedral coordination structure at the Zn2 site. Ceftazidime 213-216 cfiA Bacteroides fragilis 83-87 35131508-1 2022 BACKGROUND: In response to infection with New Delhi Metallo-beta-lactamase (NDM) producing Enterobacterales, combination antimicrobial therapy with ceftazidime/avibactam (CAZ/AVI) plus aztreonam (ATM) has been explored. Ceftazidime 148-159 ATM serine/threonine kinase Homo sapiens 196-199 35309213-9 2022 Ceftazidime and imipenem by combining avibactam (4 mug/mL) significantly decreased the MIC90 values more than 16-fold than ceftazidime and imipenem alone against Klebsiella pneumoniae carbapenemase (KPC)-2-producing K. pneumoniae. Ceftazidime 0-11 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 162-205 35019685-16 2022 The newly available beta-lactam combination agent ceftazidime-avibactam has been demonstrated good in vitro and in vivo activity against ESBL, AmpC, KPC-2, or OXA-48-like-producing isolates and has shown promise in treating carbapenem-resistant Enterobacterales infections. Ceftazidime 50-61 EsbL Escherichia coli 137-141 35019685-16 2022 The newly available beta-lactam combination agent ceftazidime-avibactam has been demonstrated good in vitro and in vivo activity against ESBL, AmpC, KPC-2, or OXA-48-like-producing isolates and has shown promise in treating carbapenem-resistant Enterobacterales infections. Ceftazidime 50-61 beta-lactamase Escherichia coli 143-147 35019685-16 2022 The newly available beta-lactam combination agent ceftazidime-avibactam has been demonstrated good in vitro and in vivo activity against ESBL, AmpC, KPC-2, or OXA-48-like-producing isolates and has shown promise in treating carbapenem-resistant Enterobacterales infections. Ceftazidime 50-61 KPC-2 Escherichia coli 149-154 2613337-5 1989 Although all the extended broad spectrum enzymes described above hydrolyzed cefotaxime, ceftazidime and aztreonam, the four enzymes could be easily differentiated: TEM-3 hydrolyzed cefotaxime preferentially, TEM-5 and RHH-1 hydrolyzed ceftazidime approximately three times faster than cefotaxime, whereas TEM-10 hydrolyzed ceftazidime 42 times faster than cefotaxime. Ceftazidime 88-99 plexin domain containing 1 Homo sapiens 164-169 34991848-9 2022 Moreover, LPC+imipenem and LPC+ceftazidime significantly decreased and increased the TNF-alpha and IL-10 levels, respectively, in comparison with the untreated controls and monotherapies. Ceftazidime 31-42 tumor necrosis factor Mus musculus 85-94 34991848-9 2022 Moreover, LPC+imipenem and LPC+ceftazidime significantly decreased and increased the TNF-alpha and IL-10 levels, respectively, in comparison with the untreated controls and monotherapies. Ceftazidime 31-42 interleukin 10 Mus musculus 99-104 2692515-4 1989 The beta-lactamase efficiently hydrolyzed cefotaxime and ceftriaxone but only moderately hydrolyzed ceftazidime and was inhibited by clavulanate and sulbactam (1 microM) and by anti-TEM-1 and anti-TEM-2 sera. Ceftazidime 100-111 hypothetical protein Escherichia coli 182-187 35203733-10 2022 Co-resistance to ceftazidime-avibactam and ceftolozane-tazobactam correlated with the presence of blaVEB-9, blaPDC-35, blaVIM-2, blaOXA-10 and blaOXA-488. Ceftazidime 17-28 VIM-2 Pseudomonas aeruginosa 119-127 2613337-5 1989 Although all the extended broad spectrum enzymes described above hydrolyzed cefotaxime, ceftazidime and aztreonam, the four enzymes could be easily differentiated: TEM-3 hydrolyzed cefotaxime preferentially, TEM-5 and RHH-1 hydrolyzed ceftazidime approximately three times faster than cefotaxime, whereas TEM-10 hydrolyzed ceftazidime 42 times faster than cefotaxime. Ceftazidime 235-246 plexin domain containing 1 Homo sapiens 164-169 2613337-5 1989 Although all the extended broad spectrum enzymes described above hydrolyzed cefotaxime, ceftazidime and aztreonam, the four enzymes could be easily differentiated: TEM-3 hydrolyzed cefotaxime preferentially, TEM-5 and RHH-1 hydrolyzed ceftazidime approximately three times faster than cefotaxime, whereas TEM-10 hydrolyzed ceftazidime 42 times faster than cefotaxime. Ceftazidime 235-246 adhesion G protein-coupled receptor A2 Homo sapiens 208-213 2613337-5 1989 Although all the extended broad spectrum enzymes described above hydrolyzed cefotaxime, ceftazidime and aztreonam, the four enzymes could be easily differentiated: TEM-3 hydrolyzed cefotaxime preferentially, TEM-5 and RHH-1 hydrolyzed ceftazidime approximately three times faster than cefotaxime, whereas TEM-10 hydrolyzed ceftazidime 42 times faster than cefotaxime. Ceftazidime 235-246 plexin domain containing 1 Homo sapiens 164-169 2613337-5 1989 Although all the extended broad spectrum enzymes described above hydrolyzed cefotaxime, ceftazidime and aztreonam, the four enzymes could be easily differentiated: TEM-3 hydrolyzed cefotaxime preferentially, TEM-5 and RHH-1 hydrolyzed ceftazidime approximately three times faster than cefotaxime, whereas TEM-10 hydrolyzed ceftazidime 42 times faster than cefotaxime. Ceftazidime 235-246 adhesion G protein-coupled receptor A2 Homo sapiens 208-213 2613337-5 1989 Although all the extended broad spectrum enzymes described above hydrolyzed cefotaxime, ceftazidime and aztreonam, the four enzymes could be easily differentiated: TEM-3 hydrolyzed cefotaxime preferentially, TEM-5 and RHH-1 hydrolyzed ceftazidime approximately three times faster than cefotaxime, whereas TEM-10 hydrolyzed ceftazidime 42 times faster than cefotaxime. Ceftazidime 88-99 adhesion G protein-coupled receptor A2 Homo sapiens 208-213 2679370-9 1989 Killing kinetics showed that against some strains CP-65,207 is rapidly bactericidal at concentrations well below those required to achieve a similar degree of killing with cefotaxime, ceftazidime, and ceftriaxone. Ceftazidime 184-195 hypothetical protein Pseudomonas aeruginosa 50-59 2675731-2 1989 Ceftazidime is very active against Pseudomonas species and provides penetration into the CSF. Ceftazidime 0-11 colony stimulating factor 2 Homo sapiens 89-92 2506109-0 1989 Substitution of serine for arginine in position 162 of TEM-type beta-lactamases extends the substrate profile of mutant enzymes, TEM-7 and TEM-101, to ceftazidime and aztreonam. Ceftazidime 151-162 plexin domain containing 1 Homo sapiens 129-134 2676935-0 1989 Mutants of the TEM-1 beta-lactamase conferring resistance to ceftazidime. Ceftazidime 61-72 TEM-1 beta-lactamase Escherichia coli 15-35 2676935-1 1989 Spontaneous ceftazidime resistant mutants were obtained from an Escherichia coli K12 J62-2 expressing the TEM-1 beta-lactamase (mutation frequency = 10(-9). Ceftazidime 12-23 TEM-1 beta-lactamase Escherichia coli 106-126 2508041-2 1989 Synergistic association (defined as FIC index less than ou = 0.5) was founded for 23 to 41% of strains with beta lactams (except imipenem)/aminoglycosides, in 18% with ceftazidime/ciprofloxacin, in 13% with imipenem/ciprofloxacin, in 0 or 13% with quinolones/aminoglycosides. Ceftazidime 168-179 C-C motif chemokine ligand 7 Homo sapiens 36-39 2508041-3 1989 For a FIC index less than ou = 0.75, the values are highest with 82% for ciprofloxacin/ceftazidime and 50% for ofloxacin/ceftazidime. Ceftazidime 87-98 C-C motif chemokine ligand 7 Homo sapiens 6-9 2508041-3 1989 For a FIC index less than ou = 0.75, the values are highest with 82% for ciprofloxacin/ceftazidime and 50% for ofloxacin/ceftazidime. Ceftazidime 121-132 C-C motif chemokine ligand 7 Homo sapiens 6-9 2663518-4 1989 Ceftazidime CSF concentrations ranged from 2.5 to 17 mg/l, which should be sufficient for treatment of infections with group B streptococci and most aerobic gram-negative bacilli but not all strains of Staphylococcus aureus. Ceftazidime 0-11 colony stimulating factor 2 Homo sapiens 12-15 2506109-1 1989 TEM-7 is a novel broad-spectrum beta-lactamase (Bla), selected in vivo, with a resistance profile similar to that of TEM-1 and TEM-2, but extended to ceftazidime (Caz) and aztreonam. Ceftazidime 150-161 plexin domain containing 1 Homo sapiens 0-5 2506109-1 1989 TEM-7 is a novel broad-spectrum beta-lactamase (Bla), selected in vivo, with a resistance profile similar to that of TEM-1 and TEM-2, but extended to ceftazidime (Caz) and aztreonam. Ceftazidime 163-166 plexin domain containing 1 Homo sapiens 0-5 2700319-4 1989 PIT-2/SHV-1 had poor hydrolytic activity against the third-generation cephalosporins, SHV-2 was markedly active against cefotaxime and related compounds, whereas the new enzyme, which was also active against these cephalosporins, had a noticeably greater activity against ceftazidime. Ceftazidime 272-283 solute carrier family 20 member 2 Homo sapiens 0-5 2550326-2 1989 The TEM-4 enzyme, which confers high-level resistance to cefotaxime (Ctx) and ceftazidime (Caz), differed from the TEM-1 penicillinase by four amino acid substitutions. Ceftazidime 78-89 Rho guanine nucleotide exchange factor 17 Homo sapiens 4-9 2550326-2 1989 The TEM-4 enzyme, which confers high-level resistance to cefotaxime (Ctx) and ceftazidime (Caz), differed from the TEM-1 penicillinase by four amino acid substitutions. Ceftazidime 78-89 CD248 molecule Homo sapiens 115-120 2550326-2 1989 The TEM-4 enzyme, which confers high-level resistance to cefotaxime (Ctx) and ceftazidime (Caz), differed from the TEM-1 penicillinase by four amino acid substitutions. Ceftazidime 91-94 Rho guanine nucleotide exchange factor 17 Homo sapiens 4-9 2550326-2 1989 The TEM-4 enzyme, which confers high-level resistance to cefotaxime (Ctx) and ceftazidime (Caz), differed from the TEM-1 penicillinase by four amino acid substitutions. Ceftazidime 91-94 CD248 molecule Homo sapiens 115-120 2973584-4 1988 Ceftazidime CSF kinetic properties are adequate for use of this compound in patients with meningitis due to susceptible organisms. Ceftazidime 0-11 colony stimulating factor 2 Homo sapiens 12-15 3145870-0 1988 In vitro interaction between the penem FCE 22101 and ceftazidime. Ceftazidime 53-64 ferrochelatase Homo sapiens 39-42 3145870-3 1988 FCE 22101 antagonized the in vitro activity of ceftazidime against enteric bacilli that commonly produce inducible enzymes. Ceftazidime 47-58 ferrochelatase Homo sapiens 0-3 2973590-2 1988 Among these compounds, ceftazidime has a particularly wide antibacterial spectrum, and clinical results have confirmed its superiority, notably in the treatment of meningitis caused by Pseudomonas spp. Ceftazidime 23-34 histocompatibility minor 13 Homo sapiens 197-200 3104483-2 1987 For E. cloacae, pre-incubation with ceftriaxone, cefoxitin, cefamandole, cefoperazone, or imipenem produced significantly larger amounts of beta-lactamase than did pre-incubation with moxalactam, clavulanate, ceftazidime, or aztreonam. Ceftazidime 209-220 Beta lactamase Pseudomonas aeruginosa 140-154 3143575-9 1988 Two Escherichia coli strains that overproduced chromosomal beta-lactamase had increased ceftazidime MIC values (8-16 micrograms/ml). Ceftazidime 88-99 beta-lactamase Escherichia coli 59-73 3144525-0 1988 In-vitro and in-vivo bacterocodal interactions of clindamycin and ceftazidime, by non-beta-lactamase mechanisms, in experimental Pseudomonas aeruginosa endocarditis caused by a constitutive beta-lactamase overproducing strain. Ceftazidime 66-77 Beta lactamase Pseudomonas aeruginosa 190-204 3069478-7 1988 The mean ceftazidime elimination half-life, apparent volume of distribution and total clearance were: 2.7 h, 30.91 (0.38 1.kg-1) and 139 ml.min-1, respectively. Ceftazidime 9-20 CD59 molecule (CD59 blood group) Homo sapiens 140-145 3069478-8 1988 A linear correlation was found between creatinine clearance and the renal clearance of the ceftazidime, the mean values being 108 and 95 ml.min-1, respectively. Ceftazidime 91-102 CD59 molecule (CD59 blood group) Homo sapiens 140-145 3530224-5 1986 The occurrence of subsequent aural drainage was compared with the actual clinical and microbiological conditions of the ears 2 months after the operation; statistically significant differences were found in favor of the group treated with ceftazidime. Ceftazidime 239-250 glutamyl-tRNA synthetase 2, mitochondrial Homo sapiens 120-126 3523458-5 1986 The mean ceftazidime CSF concentration was 6.7 micrograms/ml at approximately 2 hours following iv infusions. Ceftazidime 9-20 colony stimulating factor 2 Homo sapiens 21-24 3428136-5 1987 Ceftazidime and cefsulodin are highly active, particularly against Pseudomonas spp., thus offering new therapeutic possibilities in life-threatening infections due to these bacteria. Ceftazidime 0-11 histocompatibility minor 13 Homo sapiens 79-82 6391885-4 1984 In two other patients who had inflammatory cells and blood in the CSF, concentrations of ceftazidime in ventricular fluid demonstrated a slow rise and decline over an eight-hour period. Ceftazidime 89-100 colony stimulating factor 2 Homo sapiens 66-69 3911882-3 1985 High production of cloned E. coli chromosomal beta-lactamase, however, provided resistance to cefamandole, cefoxitin, cefotaxime, ceftazidime, and aztreonam but not to BMY-28142 or imipenem. Ceftazidime 130-141 beta-lactamase Escherichia coli 46-60 6225764-1 1983 Thirty-five patients with mean age 70 years (range 22 to 92) with 37 proven episodes of septicaemia (26) or bacteraemia (11) were treated with a mean ceftazidime dose of 1.80 (range 1 to 2 g) bid for 12 (range 3 to 17) days. Ceftazidime 150-161 BH3 interacting domain death agonist Homo sapiens 192-195 6376458-1 1984 In an infant rat model of Haemophilus influenzae, type b meningitis, where treatment was given 24 and 48 h after infection, the dose of ceftazidime required to eradicate the infection from the CSF of half the animals (CD50) ranged from less than 0.15-1.5 mg/kg/dose. Ceftazidime 136-147 colony stimulating factor 2 Rattus norvegicus 193-196 6376458-6 1984 Ceftazidime penetrated into the CSF of infected and uninfected rats slightly better than ampicillin--7.3% compared to 4.0% of the corresponding blood levels respectively. Ceftazidime 0-11 colony stimulating factor 2 Rattus norvegicus 32-35 6413485-1 1983 The competition of a new aminothiazolyl cephalosporin, ceftazidime, for the penicillin-binding proteins (PBP"s) of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus has been studied. Ceftazidime 55-66 phosphatidylethanolamine binding protein 1 Mus musculus 105-108 6413485-7 1983 aureus ceftazidime showed high affinity for PBP-1, -2 and less affinity for PBP-3. Ceftazidime 7-18 phosphatidylethanolamine binding protein 1 Mus musculus 44-47 6413485-7 1983 aureus ceftazidime showed high affinity for PBP-1, -2 and less affinity for PBP-3. Ceftazidime 7-18 phosphatidylethanolamine binding protein 1 Mus musculus 76-79 6413485-9 1983 aeruginosa, ceftazidime owes its good antibacterial activity to high affinity for PBP-3, the "essential" binding protein involved in cell division combined with favourable outer membrane penetration. Ceftazidime 12-23 phosphatidylethanolamine binding protein 1 Mus musculus 82-85 6376860-4 1984 After intravenous administration of CAZ in doses ranging from 35.7 to 50 mg/kg, CSF concentrations ranged from N.D. to 6.3 micrograms/ml in 3 patients with purulent meningitis, although 19 micrograms/ml at 1 hour and 13 micrograms/ml at 2 hours in 1 patient after intravenous administration of 46.7 mg/kg. Ceftazidime 36-39 colony stimulating factor 2 Homo sapiens 80-83 6597564-6 1984 Ceftazidime and temocillin are more long-lasting with a t1/2 of 4-6 hours and ceftriaxone of 8-10 h. These values relate to patients with normal renal function. Ceftazidime 0-11 interleukin 1 receptor like 1 Homo sapiens 56-67 6225764-12 1983 Therapy with ceftazidime 2 g bid seems to be successful in Gram-negative septicaemia; however, in patients with decreased renal function serum concentrations should be determined. Ceftazidime 13-24 BH3 interacting domain death agonist Homo sapiens 29-32 34006835-0 2021 Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction. Ceftazidime 0-11 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 85-90 6339415-3 1983 Ceftazidime displayed high stability against the beta-lactamase-producing strains with a low MBC:MIC ratio. Ceftazidime 0-11 beta-lactamase TEM-1 Haemophilus influenzae 49-63 19803009-7 1981 All the organisms were susceptible to ceftazidime (mean MIC 1.72 mg/l). Ceftazidime 38-49 growth differentiation factor 15 Homo sapiens 56-61 34006835-0 2021 Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction. Ceftazidime 0-11 angiotensin converting enzyme 2 Homo sapiens 99-103 19810169-4 1981 Both ceftazidime and ceftriaxone were highly active against beta-lactamase producing and non-beta-lactamase producing Haemophilus influenzae. Ceftazidime 5-16 beta-lactamase TEM-1 Haemophilus influenzae 60-74 19810169-4 1981 Both ceftazidime and ceftriaxone were highly active against beta-lactamase producing and non-beta-lactamase producing Haemophilus influenzae. Ceftazidime 5-16 beta-lactamase TEM-1 Haemophilus influenzae 93-107 33915286-4 2021 METHODS: Ceftazidime-avibactam resistant mutants from 3 clinical isolates of Enterobacterales carrying either blaKPC-2 or blaKPC-3 were selected in vitro. Ceftazidime 9-20 KPC-2 Escherichia coli 110-118 34007191-0 2021 Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Sequence Type 11 Due to a Mutation in Plasmid-Borne bla kpc-2 to bla kpc-33, in Henan, China. Ceftazidime 0-11 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 114-119 33737655-2 2021 Our aim was to assess the effects of antibiotic administration (ampicillin, ceftazidime, ciprofloxacin) on the establishment and elimination of intestinal colonization with a CTX-M-15 ESBL and OXA-162 carbapenemase producing Klebsiella pneumoniae ST15 (KP5825) in a murine (C57BL/6 male mice) model. Ceftazidime 76-87 extended spectrum beta-lactamase CTX-M-15 Klebsiella pneumoniae 175-183 33737655-12 2021 The gene copy number blaOXA-162 correlated with K. pneumoniae in vivo, while a major elevation was observed in the copy number of blaCTX-M-15 from the first day to the fifteenth day in the 0.5 g/L dose ceftazidime treatment group. Ceftazidime 202-213 CTX-M-15 beta-lactamase Klebsiella pneumoniae 130-141 33488575-3 2020 Screening small molecule compound libraries identified the beta-lactam antibiotics cefsulodin and ceftazidime, which inhibited integrin beta-subunit cytoplasmic domain binding to the tandem SH2 domains of Syk (IC50 range, 1.02-4.9 microM). Ceftazidime 98-109 spleen associated tyrosine kinase Homo sapiens 205-208 33291867-1 2021 Mutations in KPC-2 and KPC-3 beta-lactamase can confer resistance to the beta-lactam/beta-lactamase inhibitor antibacterial intravenous drug combination ceftazidime-avibactam, introduced in 2015. Ceftazidime 153-164 KPC-2 Escherichia coli 13-18 33367916-0 2021 Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales. Ceftazidime 33-44 mannose-binding lectin family member 3, pseudogene Homo sapiens 112-115 33488575-5 2020 Ceftazidime inhibited integrin signaling via Syk, including inhibition of adhesion-dependent upregulation of interleukin-1beta and monocyte chemoattractant protein-1, but did not inhibit ITAM-dependent phosphorylation of Syk mediated by FcgammaRI signaling. Ceftazidime 0-11 spleen associated tyrosine kinase Homo sapiens 45-48 33488575-5 2020 Ceftazidime inhibited integrin signaling via Syk, including inhibition of adhesion-dependent upregulation of interleukin-1beta and monocyte chemoattractant protein-1, but did not inhibit ITAM-dependent phosphorylation of Syk mediated by FcgammaRI signaling. Ceftazidime 0-11 interleukin 1 beta Homo sapiens 109-126 33488575-5 2020 Ceftazidime inhibited integrin signaling via Syk, including inhibition of adhesion-dependent upregulation of interleukin-1beta and monocyte chemoattractant protein-1, but did not inhibit ITAM-dependent phosphorylation of Syk mediated by FcgammaRI signaling. Ceftazidime 0-11 C-C motif chemokine ligand 2 Homo sapiens 131-165 33212285-2 2020 pneumoniae harboring NDM-1 in a neutropenic patient using aztreonam-ceftazidime-avibactam, who previously failed colistin and meropenem therapy. Ceftazidime 68-79 NDM-1 Klebsiella pneumoniae 21-26 33256982-8 2021 To test the activity of NADPH oxidase, we detected NADPH in MEM and CAZ/TB pre-cultivated activated PMNs, which showed that MEM and CAZ/TB modulates NETs formation through activation of NADHP oxidase by affecting the subunits of key enzymes. Ceftazidime 68-71 2,4-dienoyl-CoA reductase 1 Homo sapiens 24-29 33256982-8 2021 To test the activity of NADPH oxidase, we detected NADPH in MEM and CAZ/TB pre-cultivated activated PMNs, which showed that MEM and CAZ/TB modulates NETs formation through activation of NADHP oxidase by affecting the subunits of key enzymes. Ceftazidime 132-135 2,4-dienoyl-CoA reductase 1 Homo sapiens 24-29 33256982-8 2021 To test the activity of NADPH oxidase, we detected NADPH in MEM and CAZ/TB pre-cultivated activated PMNs, which showed that MEM and CAZ/TB modulates NETs formation through activation of NADHP oxidase by affecting the subunits of key enzymes. Ceftazidime 132-135 2,4-dienoyl-CoA reductase 1 Homo sapiens 51-56 32729059-0 2021 Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. Ceftazidime 13-24 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 86-91 32729059-1 2021 Three ceftazidime-avibactam-resistant KPC-2-producing Klebsiella pneumoniae strains of ST39 were isolated in Greece, from rectal swabs of three patients after 10-15 days of treatment. Ceftazidime 6-17 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 38-43 33106265-0 2020 KPC-53, a KPC-3 variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam. Ceftazidime 85-96 KPC-3 Klebsiella pneumoniae 10-15 33106265-1 2020 This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing a high-level resistance to ceftazidime-avibactam associated with production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Omega-loop and loss of carbapenemase activity. Ceftazidime 122-133 KPC-3 Klebsiella pneumoniae 184-189 33139291-7 2020 Ceftazidime-avibactam was active against 9.1% of carbapenem-resistant E. coli (63.6% were bla NDM-producers) and 84.6% of K. pneumoniae (74.3% were bla KPC-producers) isolates. Ceftazidime 0-11 beta-lactamase Escherichia coli 90-93 33139291-7 2020 Ceftazidime-avibactam was active against 9.1% of carbapenem-resistant E. coli (63.6% were bla NDM-producers) and 84.6% of K. pneumoniae (74.3% were bla KPC-producers) isolates. Ceftazidime 0-11 TEM beta-lactamase Klebsiella pneumoniae 148-151 31733412-2 2020 PATIENTS AND METHODS: A patient with an intra-abdominal infection due to K. pneumoniae producing the KPC-3 variant L169P-A172 T (resistant to ceftazidime/avibactam and susceptible to carbapenem) who was treated with imipenem-cilastatin in combination with tigecycline and gentamicin. Ceftazidime 142-153 KPC-3 Klebsiella pneumoniae 101-106 32043433-6 2020 Liquid chromatography tandem-mass spectrometry was used to determine the protein contents of the BMVs.We found that ceftazidime induced a higher number of BMVs (CAZ-BMV), which carried more LPS, and induced higher expression levels of iNOS, IL-1beta, and IL-6 in macrophages, higher expression of many cytokines in mice, more neutrophil infiltration in lung interstitium, and higher mortality in mice than imipenem-induced BMVs (IMP-BMV). Ceftazidime 116-127 nitric oxide synthase 2, inducible Mus musculus 235-239 32043433-6 2020 Liquid chromatography tandem-mass spectrometry was used to determine the protein contents of the BMVs.We found that ceftazidime induced a higher number of BMVs (CAZ-BMV), which carried more LPS, and induced higher expression levels of iNOS, IL-1beta, and IL-6 in macrophages, higher expression of many cytokines in mice, more neutrophil infiltration in lung interstitium, and higher mortality in mice than imipenem-induced BMVs (IMP-BMV). Ceftazidime 116-127 interleukin 1 alpha Mus musculus 241-249 32043433-6 2020 Liquid chromatography tandem-mass spectrometry was used to determine the protein contents of the BMVs.We found that ceftazidime induced a higher number of BMVs (CAZ-BMV), which carried more LPS, and induced higher expression levels of iNOS, IL-1beta, and IL-6 in macrophages, higher expression of many cytokines in mice, more neutrophil infiltration in lung interstitium, and higher mortality in mice than imipenem-induced BMVs (IMP-BMV). Ceftazidime 116-127 interleukin 6 Mus musculus 255-259 32660988-2 2020 We show that four steps: ompK36 and ramR mutation plus carriage of OXA-232 and KPC-3-D178Y variant beta-lactamases confer ceftazidime/avibactam and meropenem/vaborbactam resistance when both pairs are used together. Ceftazidime 122-133 KPC-3 Klebsiella pneumoniae 79-84 33257320-6 2021 High-resolution crystal structures of ESOC acyl-enzyme complexes with deacylation-deficient (E166Q) KPC-2 and KPC-4 mutants show that ceftazidime acylation causes rearrangement of three loops; the Omega-, 240- and 270-loops, that border the active site. Ceftazidime 134-145 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 100-105 33257320-7 2021 However, these rearrangements are less pronounced in the KPC-4 than the KPC-2 ceftazidime acyl-enzyme, and are not observed in the KPC-2:cefotaxime acyl-enzyme. Ceftazidime 78-89 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 72-77 33257320-8 2021 Molecular dynamics simulations of KPC:ceftazidime acyl-enyzmes reveal that the deacylation general base E166, located on the Omega-loop, adopts two distinct conformations in KPC-2, either pointing "in" or "out" of the active site; with only the "in" form compatible with deacylation. Ceftazidime 38-49 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 174-179 32719857-0 2020 Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background. Ceftazidime 106-117 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 66-71 32721602-14 2020 Resistance to ceftazidime-avibactam was highest among MDR, carbapenemase-positive, metallo-beta-lactamase (MBL)-positive K. pneumoniae (98.0%), whereas colistin resistance was highest among MDR, carbapenemase-positive, MBL-negative isolates (30.2%). Ceftazidime 14-25 hypothetical protein Klebsiella pneumoniae 83-105 32964066-1 2020 This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)-3-producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Ceftazidime 132-143 KPC-3 Klebsiella pneumoniae 39-82 32660987-3 2020 Recently, a number of clinical isolates expressing mutated forms of AmpC have been found to be clinically resistant to the antipseudomonal beta-lactam/beta-lactamase inhibitor (BLI) combinations ceftolozane/tazobactam and ceftazidime/avibactam. Ceftazidime 222-233 beta-lactamase Pseudomonas aeruginosa PAO1 68-72 32660987-10 2020 It is remarkable that these mutations enhance the catalytic efficiency of AmpC towards ceftolozane and ceftazidime while simultaneously reducing susceptibility to inhibition by avibactam. Ceftazidime 103-114 beta-lactamase Pseudomonas aeruginosa PAO1 74-78 32674904-9 2020 Moreover, LPC+imipenem and LPC+ceftazidime significantly decreased and increased the TNF-alpha and IL-10 levels, respectively, in comparison with the untreated controls and monotherapies. Ceftazidime 31-42 tumor necrosis factor Mus musculus 85-94 32259720-9 2020 Further electrocatalyzing by ring cleavage reaction and complete mineralization to CO2, NO3- and NH4+ was proposed, which demonstrated the G/CNT-Ce/PbO2-Ce electrode exhibited high efficiency for ceftazidime removal in mild conditions. Ceftazidime 196-207 NBL1, DAN family BMP antagonist Homo sapiens 88-91 32719751-10 2020 Ceftazidime-avibactam showed excellent in vitro activity against bla KPC-2 and bla OXA-48-like positive strains (100% susceptible). Ceftazidime 0-11 UBA domain containing 1 Homo sapiens 69-74 32674904-9 2020 Moreover, LPC+imipenem and LPC+ceftazidime significantly decreased and increased the TNF-alpha and IL-10 levels, respectively, in comparison with the untreated controls and monotherapies. Ceftazidime 31-42 interleukin 10 Mus musculus 99-104 32591006-7 2020 Metagenomic sequencing indicated raw milk possessed dramatically more ARGs than pasteurized milk, and a conjugation assay documented the active transfer of blaCMY-2, one ceftazidime resistance gene present in raw milk-borne E. coli, across bacterial species. Ceftazidime 170-181 AmpC Escherichia coli 156-164 32417206-8 2020 Ceftazidime-avibactam MIC values of 4 mg/L were noted among 14 Klebsiella pneumoniae (13 carrying blaKPC and 1 blaCTX-M-15) mostly from Italy and Brazil and 1 Klebsiella aerogenes overexpressing ampC. Ceftazidime 0-11 beta-lactamase Klebsiella pneumoniae 195-199 32277821-11 2020 All KPC-3-producing K. pneumoniae were susceptible to cefiderocol, even those resistant to ceftazidime/avibactam. Ceftazidime 91-102 KPC-3 Klebsiella pneumoniae 4-9 32322504-0 2020 Carbapenemase-producing Klebsiella pneumoniae intra-abdominal infection successfully treated with ceftazidime/avibactam plus tigecycline. Ceftazidime 98-109 OXA-48 Klebsiella pneumoniae 0-13 32304724-5 2020 Both assays failed to detect KPC-31 and KPC-33, D179Y point mutation variants of KPC-3 and KPC-2, that are deprived of carbapenemase activity and confer resistance to ceftazidime-avibactam. Ceftazidime 167-178 UBA domain containing 1 Homo sapiens 91-96 32742595-9 2020 Existence of bla IMP conferred more resistance to cephalotin, fosfomycin, and piperacillin (P<=0.01) and carrying bla VIM caused more resistance to cephalotin, cefepime, and ceftazidime (P<=0.01). Ceftazidime 174-185 vimentin Homo sapiens 118-121 31718408-4 2020 The objective of this study was to characterize the ESBL genes (blaTEM, blaSHV, and blaCTX-M types) that were most prevalent among 343 ceftazidime-resistant E. coli isolates (17 batches from 12 different farms) obtained from cloacal swabs of broiler chicken in southern Brazil. Ceftazidime 135-146 EsbL Escherichia coli 52-56 32196336-3 2020 Compounds 2-6 in combinations with ceftazidime and ampicillin were also efficient in restoring antibiotic efficacy in E. coli strains carrying class C (CMY-2 and DHA-1) and class A (TEM-1 and CTX-M-2) beta-lactamase enzymes, respectively. Ceftazidime 35-46 hypothetical protein Escherichia coli 182-187 32322504-1 2020 Ceftazidime/avibactam combines ceftazidime with a new beta-lactam that successfully that inhibits Amber Class A and D carbapenemases. Ceftazidime 0-11 carbapenemase KPC-2 Klebsiella pneumoniae 104-132 31742604-7 2020 A total of 394 isolates were resistant to ceftazidime/avibactam and, of the 369 isolates that were screened, 98.4% were found to carry a gene encoding an MBL enzyme. Ceftazidime 42-53 mannose-binding lectin family member 3, pseudogene Homo sapiens 154-157 31740422-8 2020 Genomic characterization showed that a ceftazidime/avibactam-resistant KPC-Kp harboured a mixed population with D179Y mutated KPC-2, while the other two ceftazidime-avibactam-resistant KPC-Kp possessed non-functional ompK35-ompK37 and mutated ompK36 porins associated with higher copy number of blaKPC gene. Ceftazidime 39-50 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 126-131 32015028-0 2020 Potency of Vaborbactam is Less Affected than Avibactam in Strains Producing KPC-2 Mutations that Confer Resistance to Ceftazidime-Avibactam. Ceftazidime 118-129 KPC-2 Pseudomonas aeruginosa 76-81 32015028-4 2020 In this study we demonstrate that two substitutions in KPC-2, D179Y and L169P, reduce the ability of avibactam to enhance the activity of ceftazidime, cefepime or piperacillin against isogenic efflux deficient strains of P. aeruginosa, 8 to 32-fold and 4 to 16-fold for the D179Y and L169P variants, respectively, depending on antibiotic. Ceftazidime 138-149 KPC-2 Pseudomonas aeruginosa 55-60 32015028-7 2020 In addition, D179Y and L169P variants hydrolyze ceftazidime with 10-fold and 4-fold higher efficiency, respectively, compared to wild-type KPC-2. Ceftazidime 48-59 KPC-2 Pseudomonas aeruginosa 139-144 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 215-226 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 215-226 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 215-226 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 215-226 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 215-226 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 215-226 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 215-226 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 215-226 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 215-226 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 31954597-4 2020 82.4% of isolates of ESBL-positive, carbapenemase-negative Enterobacteriaceae were susceptible to ceftolozane/tazobactam, compared to 1.5%, 7.8%, 20.3%, 71.1%, 94.7%, and 98.7%, respectively, for ceftriaxone, cefepime, ceftazidime, piperacillin-tazobactam, ertapenem, and meropenem. Ceftazidime 219-230 EsbL Escherichia coli 21-25 32523491-12 2020 Our conclusions are that the administration of ceftazidime as an empirical antibiotic lowers CRP level, although not significantly, while there is no decrease in several inflammatory markers. Ceftazidime 47-58 C-reactive protein Homo sapiens 93-96 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 21-32 immunoglobulin kappa variable 1-16 Homo sapiens 179-182 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 21-32 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 21-32 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 32063189-7 2020 Plasma cefazolin and ceftazidime levels increased substantially within the first few hours, peaked around 6-10 h, and sustained well above the target plasma concentrations (10 mg L-1 for cefazolin and 16 mg L-1 for ceftazidime) until 24 h. Dialysate cefazolin and ceftazidime levels were sustained above the target peritoneal concentrations (2 mg L-1 for cefazolin and 8 mg L-1 for ceftazidime) throughout the PD session except in some samples which the antibiotics levels were unusually low, probably from beta-lactamase activity. Ceftazidime 21-32 immunoglobulin kappa variable 1-16 Homo sapiens 207-210 31742604-8 2020 Among isolates that were identified as carbapenemase positive and MBL negative (n = 910), susceptibility was highest to ceftazidime/avibactam (99.8%). Ceftazidime 120-131 mannose-binding lectin family member 3, pseudogene Homo sapiens 66-69 31742604-9 2020 Susceptibility was also highest to ceftazidime/avibactam among isolates that were carbapenemase negative and MBL negative (94/98, 95.9%). Ceftazidime 35-46 mannose-binding lectin family member 3, pseudogene Homo sapiens 109-112 31992391-0 2020 Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. Ceftazidime 63-74 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 12-17 31365094-0 2019 Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. Ceftazidime 13-24 KPC-3 Klebsiella pneumoniae 49-54 31704216-0 2020 Successful treatment of septic shock due to NDM1-producing K. pneumoniae using ceftazidime-avibactam combined with aztreonam in solid organ transplant recipients: report of 2 cases. Ceftazidime 79-90 NDM-1 Klebsiella pneumoniae 44-48 31365094-2 2019 Herein, we present molecular and phenotypic characterization of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae that emerged in vivo and in vitro. Ceftazidime 64-75 KPC-3 Klebsiella pneumoniae 100-105 31365094-5 2019 RESULTS: The ceftazidime/avibactam-resistant clinical K. pneumoniae isolate revealed the amino acid change D179Y in KPC-3. Ceftazidime 13-24 KPC-3 Klebsiella pneumoniae 116-121 31365094-6 2019 Sixteen novel mutational changes in KPC-3 among in vitro-selected ceftazidime/avibactam-resistant isolates were described. Ceftazidime 66-77 KPC-3 Klebsiella pneumoniae 36-41 31527021-2 2019 The most common variant is CTX-M-15 hydrolyzing ceftazidime at high rate, but sparing carbapenems. Ceftazidime 48-59 extended spectrum beta-lactamase CTX-M-15 Klebsiella pneumoniae 27-35 31660887-11 2019 Among ESBL- producing strains, 85.7% were resistant for cefotaxime and ceftriaxone and 71.4% for ceftazidime. Ceftazidime 97-108 EsbL Escherichia coli 6-10 31527032-0 2019 Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity. Ceftazidime 97-108 KPC-3 Klebsiella pneumoniae 58-63 31127290-0 2019 Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258. Ceftazidime 8-19 OXA-2 Escherichia coli 70-75 31551966-0 2019 Ceftazidime/avibactam Improves the Antibacterial Efficacy of Polymyxin B Against Polymyxin B Heteroresistant KPC-2-Producing Klebsiella pneumoniae and Hinders Emergence of Resistant Subpopulation in vitro. Ceftazidime 0-11 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 109-114 31127290-3 2019 Here, we describe a KPC-2-encoding Klebsiella pneumoniae isolate that demonstrated reduced susceptibility to ceftazidime and ertapenem due to production of OXA-2. Ceftazidime 109-120 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 20-25 31127290-3 2019 Here, we describe a KPC-2-encoding Klebsiella pneumoniae isolate that demonstrated reduced susceptibility to ceftazidime and ertapenem due to production of OXA-2. Ceftazidime 109-120 OXA-2 Escherichia coli 156-161 31127290-4 2019 OBJECTIVES: To elucidate the role of OXA-2 production in reduced ceftazidime and ertapenem susceptibility in a K. pneumoniae ST258 clinical isolate. Ceftazidime 65-76 OXA-2 Escherichia coli 37-42 31127290-15 2019 CONCLUSIONS: Production of OXA-2 was associated with reduced ceftazidime and ertapenem susceptibility in a K. pneumoniae ST258 isolate. Ceftazidime 61-72 OXA-2 Escherichia coli 27-32 31127297-0 2019 Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. Ceftazidime 12-23 KPC-2 Escherichia coli 48-53 31127297-5 2019 RESULTS: Susceptibility testing revealed that Escherichia coli producing KPC-28 displayed MICs that were lower for carbapenems and higher for ceftazidime and ceftazidime/avibactam as compared with KPC-2. Ceftazidime 142-153 KPC-2 Escherichia coli 73-78 31127297-5 2019 RESULTS: Susceptibility testing revealed that Escherichia coli producing KPC-28 displayed MICs that were lower for carbapenems and higher for ceftazidime and ceftazidime/avibactam as compared with KPC-2. Ceftazidime 158-169 KPC-2 Escherichia coli 73-78 31225611-1 2019 OBJECTIVES: To evaluate the efficacy of the recently launched beta-lactam/beta-lactamase inhibitor combinations ceftazidime/avibactam and ceftolozane/tazobactam against ESBL-producing Escherichia coli and Pseudomonas aeruginosa strains. Ceftazidime 112-123 EsbL Escherichia coli 169-173 31135647-0 2019 Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age. Ceftazidime 7-18 adenosine deaminase 2 Homo sapiens 80-83 31002313-1 2019 OBJECTIVES: Our aim was to determine the epidemiology of bloodstream infections (BSIs) by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) after the introduction of ceftazidime/avibactam in January 2018 among ICU patients. Ceftazidime 170-181 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens 137-142 31002313-10 2019 CONCLUSIONS: Widespread ceftazidime/avibactam use may lead to a change in the palette of carbapenemases by replacing KPC with MBL-producing isolates. Ceftazidime 24-35 mannose-binding lectin family member 3, pseudogene Homo sapiens 126-129 31308713-0 2019 Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in bla KPC-3-harboring Klebsiella pneumoniae. Ceftazidime 78-89 KPC-3 Klebsiella pneumoniae 118-123 31130090-0 2019 In vitro activity of ceftazidime/avibactam against clinical isolates of ESBL-producing Enterobacteriaceae in Italy. Ceftazidime 21-32 EsbL Escherichia coli 72-76 31130090-3 2019 Ceftazidime/avibactam (CZA) is a new combination of a third generation cephalosporin and a non-beta-lactam beta-lactamase inhibitor, in which avibactam is capable to expand the ceftazidime activity also against extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Ceftazidime 0-11 EsbL Escherichia coli 245-249 31225611-5 2019 RESULTS: We showed here an overall better activity of ceftazidime/avibactam compared with ceftolozane/tazobactam toward ESBL-producing E. coli and P. aeruginosa. Ceftazidime 54-65 EsbL Escherichia coli 120-124 31225611-10 2019 Excellent activity of ceftazidime/avibactam was highlighted for both ESBL-producing E. coli and ESBL-producing P. aeruginosa. Ceftazidime 22-33 EsbL Escherichia coli 69-73 31225611-10 2019 Excellent activity of ceftazidime/avibactam was highlighted for both ESBL-producing E. coli and ESBL-producing P. aeruginosa. Ceftazidime 22-33 EsbL Escherichia coli 96-100 30753505-10 2019 All isolates resistant to ceftolozane/tazobactam and ceftazidime/avibactam (Greece, n = 10; and Italy, n = 2) carried blaVIM-2. Ceftazidime 53-64 VIM-2 Pseudomonas aeruginosa 118-126 31579237-4 2019 ESBL detection was confirmed by minimal inhibitory concentration method using agar dilution technique for those who screened positive by ceftazidime (30 mug) disc. Ceftazidime 137-148 EsbL Escherichia coli 0-4 31088601-1 2019 In December 2018, a ceftazidime-avibactam (CAZ-AVI)-resistant KPC-2-producing Klebsiella pneumoniae strain was isolated in Finland. Ceftazidime 20-31 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 62-67 30753505-16 2019 blaVIM-2 is associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam, and related to highly resistant phenotypes. Ceftazidime 69-80 VIM-2 Pseudomonas aeruginosa 0-8 30753572-0 2019 Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. Ceftazidime 0-11 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 85-90 30753572-1 2019 OBJECTIVES: Ceftazidime/avibactam resistance due to mutation in the omega loop of KPC-2 has been documented in vitro and in vivo. Ceftazidime 12-23 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 82-87 30753572-2 2019 This study evaluated the mechanism of ceftazidime/avibactam resistance in a KPC-2-expressing Klebsiella pneumoniae isolated from a patient following ceftazidime/avibactam combination therapy with gentamicin for the treatment of ventilator-associated pneumonia. Ceftazidime 38-49 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 76-81 30753572-2 2019 This study evaluated the mechanism of ceftazidime/avibactam resistance in a KPC-2-expressing Klebsiella pneumoniae isolated from a patient following ceftazidime/avibactam combination therapy with gentamicin for the treatment of ventilator-associated pneumonia. Ceftazidime 149-160 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 76-81 30753572-4 2019 The KPC-2 gene was cloned from the ceftazidime/avibactam-resistant isolate and evaluated for susceptibility to ceftazidime/avibactam, in an Escherichia coli background. Ceftazidime 35-46 KPC-2 Escherichia coli 4-9 30753572-4 2019 The KPC-2 gene was cloned from the ceftazidime/avibactam-resistant isolate and evaluated for susceptibility to ceftazidime/avibactam, in an Escherichia coli background. Ceftazidime 111-122 KPC-2 Escherichia coli 4-9 30753572-5 2019 RESULTS: A single L169P mutation was identified in the KPC-2 gene between the ceftazidime/avibactam-resistant and -susceptible isolates. Ceftazidime 78-89 KPC-2 Escherichia coli 55-60 30753572-6 2019 The novel KPC-2 allele, designated KPC-35, was shown to confer reduced susceptibility to ceftazidime/avibactam and increased susceptibility to carbapenems, as compared with KPC-2. Ceftazidime 89-100 KPC-2 Escherichia coli 10-15 30753572-7 2019 CONCLUSIONS: A novel L169P mutation was identified in KPC-2 and was shown through cloning experiments to confer reduced susceptibility to ceftazidime/avibactam. Ceftazidime 138-149 KPC-2 Escherichia coli 54-59 30617091-4 2019 Among the CRE, 50.8% (189/372 isolates) were positive for bla KPC-2, which mainly existed in ceftazidime-avibactam-susceptible Klebsiella pneumoniae isolates (92.1%, 174/189). Ceftazidime 93-104 KPC-2 protein Klebsiella pneumoniae 58-67 30479755-19 2018 Conclusion: This study indicated ceftazidime-avibactam therapy occupied significant bactericidal effects against KPC-2 and OXA-232 carbapenemase-producing Klebsiella pneumoniae. Ceftazidime 33-44 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 113-118 30755518-6 2019 Treatment of THP-1 human macrophages infected with three different M. abscessus clinical isolates supported the in vitro findings, as the combination of 100 microg/ml ceftazidime and 0.125 microg/ml ceftaroline or 100 microg/ml ceftazidime and 0.25 microg/ml imipenem dramatically reduced the CFU counts to near baseline levels of infection. Ceftazidime 167-178 GLI family zinc finger 2 Homo sapiens 13-18 30755518-9 2019 Our recent discoveries that dual beta-lactams, specifically the combination of ceftazidime with ceftaroline or ceftazidime with imipenem, have significant in vitro MIC values and kill curve activities and are effective against infected THP-1 human macrophages provide optimism for a dual beta-lactam treatment strategy against MABC infections. Ceftazidime 79-90 GLI family zinc finger 2 Homo sapiens 236-241 30755518-9 2019 Our recent discoveries that dual beta-lactams, specifically the combination of ceftazidime with ceftaroline or ceftazidime with imipenem, have significant in vitro MIC values and kill curve activities and are effective against infected THP-1 human macrophages provide optimism for a dual beta-lactam treatment strategy against MABC infections. Ceftazidime 111-122 GLI family zinc finger 2 Homo sapiens 236-241 31424008-0 2019 Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from In vitro study. Ceftazidime 5-16 OXA-48 Klebsiella pneumoniae 67-73 31424008-2 2019 Newer Food and Drug Administration-approved antimicrobial ceftazidime/avibactam (C/A) has a potent activity against bla OXA-48-like producers. Ceftazidime 58-69 TEM beta-lactamase Klebsiella pneumoniae 116-119 31424008-2 2019 Newer Food and Drug Administration-approved antimicrobial ceftazidime/avibactam (C/A) has a potent activity against bla OXA-48-like producers. Ceftazidime 58-69 OXA-48 Klebsiella pneumoniae 120-126 30622934-6 2018 According to our in vitro susceptibility study based on growth curves, NADPH restored the antibacterial activity of ceftazidime against a ceftazidime-resistant Escherichia coli BER strain producing AmpC BER. Ceftazidime 116-127 2,4-dienoyl CoA reductase 1, mitochondrial Mus musculus 71-76 30622934-6 2018 According to our in vitro susceptibility study based on growth curves, NADPH restored the antibacterial activity of ceftazidime against a ceftazidime-resistant Escherichia coli BER strain producing AmpC BER. Ceftazidime 138-149 2,4-dienoyl CoA reductase 1, mitochondrial Mus musculus 71-76 30622934-7 2018 Remarkably, a single dose of combinatory treatment with NADPH and ceftazidime conferred marked therapeutic efficacy (100% survival rate) in a mouse model infected by the E. coli BER strain although NADPH or ceftazidime alone failed to prevent the lethal bacterial infection. Ceftazidime 66-77 2,4-dienoyl CoA reductase 1, mitochondrial Mus musculus 198-203 30622934-7 2018 Remarkably, a single dose of combinatory treatment with NADPH and ceftazidime conferred marked therapeutic efficacy (100% survival rate) in a mouse model infected by the E. coli BER strain although NADPH or ceftazidime alone failed to prevent the lethal bacterial infection. Ceftazidime 207-218 2,4-dienoyl CoA reductase 1, mitochondrial Mus musculus 56-61 30044946-1 2018 Ceftazidime/avibactam plus aztreonam (CZA+ATM) is an emerging option to combat carbapenemase-producing Enterobacteriaceae (CPE) expressing resistance via multiple beta-lactamases within Ambler classes A, B, C, and D. The benefit of this combination is apparent when the pathogen-specific resistance genotype is characterized. Ceftazidime 0-11 ATM serine/threonine kinase Homo sapiens 42-45 30532496-12 2018 Antibiogram of these ESBL-positive isolates revealed the drugs such as colistin (100%), levofloxacin (83.33%), and imipenem (66.67%) to be highly sensitive against this pathogen but drugs such as cefotaxime (100%), ceftazidime (91.67%), amoxicillin/clavulanic acid (83.33%), tetracycline (75.00%), and gentamicin (58.33%) to be very much resistant. Ceftazidime 215-226 EsbL Escherichia coli 21-25 30081137-6 2018 The reduction of ceftazidime MIC in the presence of avibactam was partially lost for isolates with large efflux activity of MexAB-OprM and/or increased ampC expression, but not significantly with mexE expression or lack of OprD (non-parametric and parametric tests). Ceftazidime 17-28 outer membrane protein OprM Pseudomonas aeruginosa PAO1 130-134 30081137-6 2018 The reduction of ceftazidime MIC in the presence of avibactam was partially lost for isolates with large efflux activity of MexAB-OprM and/or increased ampC expression, but not significantly with mexE expression or lack of OprD (non-parametric and parametric tests). Ceftazidime 17-28 porin D Pseudomonas aeruginosa PAO1 223-227 30081137-0 2018 Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis. Ceftazidime 20-31 outer membrane protein OprM Pseudomonas aeruginosa PAO1 55-59 30081137-3 2018 Using the laboratory strain PAO1 and derivatives thereof, with ampC expression induced by a sub-minimum inhibitory concentration (MIC) of imipenem, a higher MIC of ceftazidime-avibactam was found for those overexpressing MexAB-OprM (quantitative polymerase chain reaction (PCR) of mexA) and, to a lesser extent, MexEF-OprN (PCR of mexE), or without OprD expression (SDS-Page and Coomassie blue staining). Ceftazidime 164-175 outer membrane protein OprM Pseudomonas aeruginosa PAO1 227-231 30081137-3 2018 Using the laboratory strain PAO1 and derivatives thereof, with ampC expression induced by a sub-minimum inhibitory concentration (MIC) of imipenem, a higher MIC of ceftazidime-avibactam was found for those overexpressing MexAB-OprM (quantitative polymerase chain reaction (PCR) of mexA) and, to a lesser extent, MexEF-OprN (PCR of mexE), or without OprD expression (SDS-Page and Coomassie blue staining). Ceftazidime 164-175 porin D Pseudomonas aeruginosa PAO1 349-353 30258039-10 2018 The heterogenous population of wild-type and mutated bla KPC-2 and the reversibility of the genotypes observed suggest a significant challenge for managing KPC-producing isolates that develop ceftazidime-avibactam resistance during therapy.IMPORTANCE The development of ceftazidime-avibactam resistance among KPC-producing isolates during treatment with this agent has been reported. Ceftazidime 270-281 KPC-2 Escherichia coli 57-62 29991562-2 2018 Meropenem and piperacillin/tazobactam (PIP/TZB) are recommended for the treatment of peritoneal dialysis-associated peritonitis (PDAP) caused by ceftazidime-resistant Pseudomonas and other resistant gram-negative bacteria. Ceftazidime 145-156 prolactin induced protein Homo sapiens 39-42 30010894-4 2018 Results: Ceftazidime/avibactam was the most active agent, compared with all other tested comparator agents, against the overall collection of Enterobacteriaceae isolates (99.4% susceptible) and against subsets of ceftazidime-non-susceptible (97.7% susceptible), colistin-resistant (98.2% susceptible), MDR (96.7% susceptible) and meropenem-non-susceptible, MBL-negative (98.5% susceptible) isolates. Ceftazidime 9-20 mannose-binding lectin family member 3, pseudogene Homo sapiens 357-360 30258039-0 2018 Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying bla KPC-2 Reveals a Heterogenous Population and Reversible Genotype. Ceftazidime 14-25 beta-lactamase Escherichia coli 84-87 29980462-3 2018 METHODS: At an urban public hospital in Northern California, microbiology staff prospectively reviewed ED urine culture results weekly for 1 year and presumptively identified ESBL-producing isolates by ceftriaxone plus ceftazidime resistance. Ceftazidime 219-230 EsbL Escherichia coli 175-179 30258039-0 2018 Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying bla KPC-2 Reveals a Heterogenous Population and Reversible Genotype. Ceftazidime 14-25 KPC-2 Escherichia coli 88-93 30258039-11 2018 Usually isolates that become resistant have a mutated bla KPC gene that confers resistance to ceftazidime-avibactam and susceptibility to meropenem. Ceftazidime 94-105 beta-lactamase Escherichia coli 54-57 30258039-1 2018 A bla KPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent. Ceftazidime 60-71 beta-lactamase Escherichia coli 2-5 30258039-1 2018 A bla KPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent. Ceftazidime 60-71 KPC-2 Escherichia coli 6-11 30258039-7 2018 Recombinant plasmids carrying the bla KPC-2 alterations observed were transformed in Escherichia coli, and MIC values for ceftazidime +- avibactam were elevated. Ceftazidime 122-133 beta-lactamase Escherichia coli 34-37 30258039-7 2018 Recombinant plasmids carrying the bla KPC-2 alterations observed were transformed in Escherichia coli, and MIC values for ceftazidime +- avibactam were elevated. Ceftazidime 122-133 KPC-2 Escherichia coli 38-43 30258039-10 2018 The heterogenous population of wild-type and mutated bla KPC-2 and the reversibility of the genotypes observed suggest a significant challenge for managing KPC-producing isolates that develop ceftazidime-avibactam resistance during therapy.IMPORTANCE The development of ceftazidime-avibactam resistance among KPC-producing isolates during treatment with this agent has been reported. Ceftazidime 192-203 KPC-2 Escherichia coli 57-62 30258039-12 2018 We report a Citrobacter freundii isolate that developed ceftazidime-avibactam resistance due to mutations within the coding region of the bla KPC-2 Omega-loop previously reported; however, in this case, only 11% of the whole-genome sequencing reads had mutations, making this alteration difficult to detect and the treatment of these isolates more challenging. Ceftazidime 56-67 beta-lactamase Escherichia coli 138-141 30258039-12 2018 We report a Citrobacter freundii isolate that developed ceftazidime-avibactam resistance due to mutations within the coding region of the bla KPC-2 Omega-loop previously reported; however, in this case, only 11% of the whole-genome sequencing reads had mutations, making this alteration difficult to detect and the treatment of these isolates more challenging. Ceftazidime 56-67 KPC-2 Escherichia coli 142-147 29941650-0 2018 Combination of Amino Acid Substitutions Leading to CTX-M-15-Mediated Resistance to the Ceftazidime-Avibactam Combination. Ceftazidime 87-98 hypothetical protein Escherichia coli 51-59 30053579-8 2018 Resistance to ceftazidime could be attributed to AmpC cephalosporinase encoded by blaADC-25, and to blaNDM-1 on plasmids. Ceftazidime 14-25 beta-lactamase NDM-1 Acinetobacter baumannii 100-108 29990693-8 2018 Furthermore, the levels of inflammatory factors IL-1beta, IFN-gamma and TNF-alpha were decreased after CXCL8-IP10, dexamethasone or ceftazidime treatment. Ceftazidime 132-143 C-X-C motif chemokine ligand 8 Homo sapiens 103-108 29941650-9 2018 Resistance to the drug combination (MIC of ceftazidime, 16 mug/ml in the presence of 4 mug/ml of avibactam) resulted from the acquisition of the S130G substitution by CTX-M-15 L169Q. Ceftazidime 43-54 hypothetical protein Escherichia coli 167-175 29941650-10 2018 Purified CTX-M-15 with the two substitutions, L169Q and S130G, was only partially inhibited by avibactam at concentrations as high as 50,000 muM but retained ceftazidime hydrolysis activity with partially compensatory decreases in kcat and Km These results indicate that emergence of resistance to the ceftazidime-avibactam combination requires more than one mutation in most CTX-M-encoding genes. Ceftazidime 158-169 hypothetical protein Escherichia coli 9-17 29941650-10 2018 Purified CTX-M-15 with the two substitutions, L169Q and S130G, was only partially inhibited by avibactam at concentrations as high as 50,000 muM but retained ceftazidime hydrolysis activity with partially compensatory decreases in kcat and Km These results indicate that emergence of resistance to the ceftazidime-avibactam combination requires more than one mutation in most CTX-M-encoding genes. Ceftazidime 302-313 hypothetical protein Escherichia coli 9-17 29682477-5 2018 The isolates of ESBL were confirmed by ceftazidime/clavulanic acid and cefotaxime/clavulanic acid method. Ceftazidime 39-50 EsbL Escherichia coli 16-20 29709981-0 2018 Plasmid-Mediated AmpC beta-Lactamase and Underestimation of Extended-Spectrum beta-Lactamase in Cefepime-Susceptible Elevated-Ceftazidime-MIC Enterobacteriaceae Isolates. Ceftazidime 126-137 EsbL Escherichia coli 60-92 30087569-7 2018 The transpositions resulted in novel larger blaCMY-2-harboring ColE1-like plasmids with size of 14,845 bp, enabling increase in MICs of 2 to 8-fold for cefotaxime, ceftiofur, and ceftazidime in recipient strains over their respective original counterparts. Ceftazidime 179-190 AmpC Escherichia coli 44-52 29263067-0 2018 Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates. Ceftazidime 24-35 KPC-2 protein Klebsiella pneumoniae 97-105 29272413-0 2018 Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. Ceftazidime 51-62 NDM-1 Klebsiella pneumoniae 91-103 29535301-1 2018 Extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) strains are emerging around the world as a source of resistance to beta-lactam antibiotics such as ampicillin, cefotaxime, and ceftazidime. Ceftazidime 197-208 EsbL Escherichia coli 61-65 29191131-0 2018 Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2. Ceftazidime 12-23 KPC-2 protein Klebsiella pneumoniae 162-170 29527530-4 2018 Oxyimino-cephalosporins, such as cefotaxime and ceftazidime, however, are poor substrates for TEM-1 and were introduced, in part, to circumvent beta-lactamase-mediated resistance. Ceftazidime 48-59 CD248 molecule Homo sapiens 94-99 29021086-0 2017 Genomic characterization of an extensively drug-resistant KPC-2-producing Klebsiella pneumoniae ST855 (CC258) only susceptible to ceftazidime-avibactam isolated in Brazil. Ceftazidime 130-141 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 58-63 29255163-6 2017 Interestingly, this work also allowed the identification of potent KPC-2 and NDM-1 inhibitors able to potentiate the activity of cefotaxime (CTX) and ceftazidime (CAZ) against resistant clinical isolates (MIC reduction, 32-fold). Ceftazidime 150-161 UBA domain containing 1 Homo sapiens 67-72 29255163-6 2017 Interestingly, this work also allowed the identification of potent KPC-2 and NDM-1 inhibitors able to potentiate the activity of cefotaxime (CTX) and ceftazidime (CAZ) against resistant clinical isolates (MIC reduction, 32-fold). Ceftazidime 163-166 UBA domain containing 1 Homo sapiens 67-72 28739787-2 2017 Recently, reports have emerged of KPC-producing isolates resistant to this antibiotic, including a report of a wild-type KPC-3 producing sequence type 258 Klebsiella pneumoniae that was resistant to ceftazidime-avibactam. Ceftazidime 199-210 KPC-3 Klebsiella pneumoniae 121-126 28693993-0 2017 Probing the interaction of cephalosporin antibiotic-ceftazidime with human serum albumin: A biophysical investigation. Ceftazidime 52-63 albumin Homo sapiens 75-88 28693993-3 2017 In the present study, we have explored the mechanism of interaction between cephalosporin antibiotic-ceftazidime (CFD) and human serum albumin (HSA) by spectroscopic and molecular docking studies. Ceftazidime 101-112 albumin Homo sapiens 129-142 28925926-4 2017 RESULTS: After tap-and-inject treatment of endophthalmitis with ceftazidime, vancomycin, and dexamethasone, the patient returned for follow-up with visual improvement and resolution of the subretinal fluid. Ceftazidime 64-75 nuclear RNA export factor 1 Homo sapiens 15-18 28961715-7 2017 Against a K. pneumoniae strain with blaOXA-48, ceftazidime had a lower MIC (0.5 mg/L) than cefotaxime (2 mg/L). Ceftazidime 47-58 OXA-48 Klebsiella pneumoniae 36-45 28739787-5 2017 In addition, we demonstrate that the increased expression of blaKPC-3 and blaSHV-12 observed in the ceftazidime-avibactam-resistant isolate was due to transposition of the Tn4401 transposon harboring blaKPC-3 into a second plasmid, pIncX3, which also harbored blaSHV-12, ultimately resulting in a higher copy number of blaKPC-3 in the resistant isolate. Ceftazidime 100-111 beta-lactamase KPC-3 Klebsiella pneumoniae 61-69 28739787-5 2017 In addition, we demonstrate that the increased expression of blaKPC-3 and blaSHV-12 observed in the ceftazidime-avibactam-resistant isolate was due to transposition of the Tn4401 transposon harboring blaKPC-3 into a second plasmid, pIncX3, which also harbored blaSHV-12, ultimately resulting in a higher copy number of blaKPC-3 in the resistant isolate. Ceftazidime 100-111 beta-lactamase KPC-3 Klebsiella pneumoniae 200-208 28739787-5 2017 In addition, we demonstrate that the increased expression of blaKPC-3 and blaSHV-12 observed in the ceftazidime-avibactam-resistant isolate was due to transposition of the Tn4401 transposon harboring blaKPC-3 into a second plasmid, pIncX3, which also harbored blaSHV-12, ultimately resulting in a higher copy number of blaKPC-3 in the resistant isolate. Ceftazidime 100-111 beta-lactamase KPC-3 Klebsiella pneumoniae 200-208 28696058-12 2017 Ceftazidime reduced Renin expression by 1.7-fold (p < 0.01). Ceftazidime 0-11 renin Rattus norvegicus 20-25 28927454-6 2017 Extended spectrum beta-lactamase production was detected by combined disc method using ceftazidime and ceftazidime/clavulanic acid discs and cefotaxime and cefotaxime/clavulanic acid discs. Ceftazidime 87-98 EsbL Escherichia coli 0-32 28927454-6 2017 Extended spectrum beta-lactamase production was detected by combined disc method using ceftazidime and ceftazidime/clavulanic acid discs and cefotaxime and cefotaxime/clavulanic acid discs. Ceftazidime 103-114 EsbL Escherichia coli 0-32 28696058-13 2017 CONCLUSION: Our experiments showed that gentamicin at clinical levels did not disturb kidney development, ceftazidime can affect Renin expression, and extrauterine growth restriction impairs kidney development, but did not modulate potential drug toxicity. Ceftazidime 106-117 renin Rattus norvegicus 129-134 28685153-1 2017 We used meropenem to successfully treat a patient with bacteremia due to ceftazidime-avibactam-resistant, meropenem- susceptible Klebsiella pneumoniae that carried mutant blaKPC-3. Ceftazidime 73-84 beta-lactamase KPC-3 Klebsiella pneumoniae 171-179 28637339-2 2017 We here report on the emergence of ceftazidime/avibactam resistance in clinical, multiresistant, OXA-48 and CTX-M-14-producing Klebsiella pneumoniae isolate DT12 during ceftazidime/avibactam treatment. Ceftazidime 35-46 beta-lactamase CTX-M-14 Klebsiella pneumoniae 108-116 28637339-2 2017 We here report on the emergence of ceftazidime/avibactam resistance in clinical, multiresistant, OXA-48 and CTX-M-14-producing Klebsiella pneumoniae isolate DT12 during ceftazidime/avibactam treatment. Ceftazidime 169-180 beta-lactamase CTX-M-14 Klebsiella pneumoniae 108-116 28637339-4 2017 Compared with WT CTX-M-14, expression of the CTX-M-14Delta170Delta264 isoform in Escherichia coli led to a >64- and 16-fold increase in ceftazidime and ceftazidime/avibactam MICs, respectively, functionally linking the observed SNPs and elevated MICs. Ceftazidime 139-150 CTX-M-14 Escherichia coli 17-25 28637339-5 2017 The mutated CTX-M-14 isoform exhibited augmented ceftazidime hydrolytic activity, which was a reasonable cause for impaired susceptibility to avibactam inhibition. Ceftazidime 49-60 beta-lactamase CTX-M-14 Klebsiella pneumoniae 12-20 28637339-6 2017 The P170S exchange in CTX-M-14 was found in association with elevated ceftazidime/avibactam MICs for independent K. pneumoniae isolates, but was not sufficient for full resistance. Ceftazidime 70-81 beta-lactamase CTX-M-14 Klebsiella pneumoniae 22-30 28637339-9 2017 Despite sustained inhibition of OXA-48, rapid development of CTX-M-14 isoforms exhibiting augmented ceftazidime hydrolytic activity may limit the usefulness of ceftazidime/avibactam monotherapies in infections caused by isolates carrying blaCTX-M-14 and blaOXA-48. Ceftazidime 100-111 beta-lactamase CTX-M-14 Klebsiella pneumoniae 61-69 28637339-9 2017 Despite sustained inhibition of OXA-48, rapid development of CTX-M-14 isoforms exhibiting augmented ceftazidime hydrolytic activity may limit the usefulness of ceftazidime/avibactam monotherapies in infections caused by isolates carrying blaCTX-M-14 and blaOXA-48. Ceftazidime 100-111 CTX-M-14 Klebsiella pneumoniae 238-249 28637339-9 2017 Despite sustained inhibition of OXA-48, rapid development of CTX-M-14 isoforms exhibiting augmented ceftazidime hydrolytic activity may limit the usefulness of ceftazidime/avibactam monotherapies in infections caused by isolates carrying blaCTX-M-14 and blaOXA-48. Ceftazidime 100-111 OXA-48 Klebsiella pneumoniae 254-263 28637339-9 2017 Despite sustained inhibition of OXA-48, rapid development of CTX-M-14 isoforms exhibiting augmented ceftazidime hydrolytic activity may limit the usefulness of ceftazidime/avibactam monotherapies in infections caused by isolates carrying blaCTX-M-14 and blaOXA-48. Ceftazidime 160-171 beta-lactamase CTX-M-14 Klebsiella pneumoniae 61-69 28630202-9 2017 The presence of variant KPC-3 was associated with ceftazidime-avibactam resistance (P < 0.0001). Ceftazidime 50-61 KPC-3 Klebsiella pneumoniae 24-29 28242667-0 2017 In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases. Ceftazidime 49-60 KPC-3 Klebsiella pneumoniae 148-153 28461318-0 2017 Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 beta-Lactamase. Ceftazidime 55-66 beta-lactamase Klebsiella pneumoniae 132-146 28804585-10 2017 There was a correlation (p < 0.001) between expression of CTX-M-15 and resistance to ceftazidime. Ceftazidime 88-99 hypothetical protein Escherichia coli 61-69 28223379-0 2017 Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum beta-Lactamases. Ceftazidime 34-45 beta-lactamase KPC-3 Klebsiella pneumoniae 13-21 28223379-1 2017 We identified four blaKPC-3 mutations in ceftazidime-avibactam-resistant clinical Klebsiella pneumoniae isolates, corresponding to D179Y, T243M, D179Y/T243M, and EL165-166 KPC-3 variants. Ceftazidime 41-52 beta-lactamase KPC-3 Klebsiella pneumoniae 19-27 28242667-1 2017 Ceftazidime-avibactam resistance is mediated by blaKPC-3 mutations, which restore carbapenem susceptibility. Ceftazidime 0-11 beta-lactamase KPC-3 Klebsiella pneumoniae 48-56 28223379-2 2017 Using site-directed mutagenesis and transforming vectors into Escherichia coli, we conclusively demonstrated that mutant blaKPC-3 encoded enzymes that functioned as extended-spectrum beta-lactamases; mutations directly conferred higher MICs of ceftazidime-avibactam and decreased the MICs of carbapenems and other beta-lactams. Ceftazidime 244-255 beta-lactamase KPC-3 Klebsiella pneumoniae 121-129 25442872-12 2016 Administration of fosfomycin plus amikacin or ceftazidime was an effective therapeutic and preventive strategy in children with VUR and recurrent relapsing UTI. Ceftazidime 46-57 VUR Homo sapiens 128-131 28031201-0 2017 Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Ceftazidime 13-24 beta-lactamase KPC-3 Klebsiella pneumoniae 67-75 28031201-11 2017 In conclusion, the development of resistance-conferring blaKPC-3 mutations in K. pneumoniae within 10 to 19 days of ceftazidime-avibactam exposure is troubling, but clinical impact may be ameliorated if carbapenem susceptibility is restored in certain isolates. Ceftazidime 116-127 beta-lactamase KPC-3 Klebsiella pneumoniae 56-64 28069651-6 2017 The hydrolysis of amoxicillin and nitrocefin by KPC-2 and CTX-M-15 was moderately affected by the substitution N132G, but that of ceftazidime, ceftaroline, and aztreonam was drastically reduced. Ceftazidime 130-141 UBA domain containing 1 Homo sapiens 48-53 27584588-5 2016 Ceftazidime-avibactam may be an effective therapeutic agent for infections caused by carbapenem-hydrolyzing oxacillinase-48 and Klebsiella pneumoniae carbapenamase-producing Enterobacteriaceae, but not for New Delhi metallo-beta-lactamase producers. Ceftazidime 0-11 NDM-1 Klebsiella pneumoniae 206-238 28812563-3 2016 The plasmid accelerated resistance evolution by increasing the rate of appearance of novel TEM-1 mutations, thereby conferring resistance to ceftazidime, and then by amplifying the effect of TEM-1 mutations due to the increased gene dosage. Ceftazidime 141-152 hypothetical protein Escherichia coli 91-96 27889371-5 2017 Analysis of blaSHV open-reading frame showed that blaSHV-5 had a high hydrolysis activity to the broad-spectrum penicillin (ampicillin or piperacillin), ceftazidime, ceftriaxone, cefotaxime and aztreonam. Ceftazidime 153-164 BlaSHV-5 Escherichia coli 50-58 27624957-0 2016 Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We"re Gonna Need a Bigger Boat". Ceftazidime 22-33 ataxin 1 like Homo sapiens 116-121 27392786-3 2016 The ESBL phenotype was determined with the Clinical and Laboratory Standards Institute confirmatory broth microdilution test using cefotaxime and ceftazidime with and without clavulanate. Ceftazidime 146-157 EsbL Escherichia coli 4-8 27488224-12 2016 CONCLUSION: Based on the findings of our study, we recommend to use ceftazidime/clavulanate combination for phenotypic confirmation of ESBL producers. Ceftazidime 68-80 EsbL Escherichia coli 135-139 27221329-4 2016 One substantial PLIE was found: a value of 1 9 h for ceftazidime-avibactam against Klebsiella pneumoniae (blaKPC-2 ). Ceftazidime 53-64 KPC-2 protein Klebsiella pneumoniae 106-114 27396948-0 2016 Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient. Ceftazidime 45-56 KPC-3 Klebsiella pneumoniae 73-78 27216075-1 2016 Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against beta-Lactamase-Producing Isolates. Ceftazidime 37-48 beta-lactamase Klebsiella pneumoniae 74-88 27216075-9 2016 Ceftazidime-avibactam, a recently approved beta-lactamase inhibitor combination, was very active against the ESBL phenotype isolates (MIC50/90, 0.12 and 1 mug/ml; 99.7% susceptible) and CRE strains (MIC50/90, 0.5 and 2 mug/ml; 98.5% susceptible) that displayed elevated MIC values for many comparator agents. Ceftazidime 0-11 beta-lactamase Klebsiella pneumoniae 43-57 26419415-0 2016 Increased resistance rate to ceftazidime among blood culture isolates of ESBL-producing Escherichia coli in a university-affiliated hospital of China. Ceftazidime 29-40 EsbL Escherichia coli 73-77 26920105-6 2016 Among VABP isolates, MIC90 values for ceftazidime/avibactam against E. coli were 0.25mg/L; for Klebsiella spp. Ceftazidime 38-49 potassium voltage-gated channel interacting protein 1 Homo sapiens 6-10 26920105-10 2016 However, ceftazidime/avibactam inhibited 79.2-95.4% of VABP isolates at an MIC of <=8mg/L. Ceftazidime 9-20 potassium voltage-gated channel interacting protein 1 Homo sapiens 55-59 26920105-13 2016 Ceftazidime/avibactam was generally active against a high proportion of isolates resistant to ceftazidime from PHP and VAPB patients. Ceftazidime 0-11 VAMP associated protein B and C Homo sapiens 119-123 26920105-13 2016 Ceftazidime/avibactam was generally active against a high proportion of isolates resistant to ceftazidime from PHP and VAPB patients. Ceftazidime 94-105 VAMP associated protein B and C Homo sapiens 119-123